[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNL5svsFrsGBcUgCfHjhtjntZ5CcHj5jxxXNWhWjPlnM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Dr. Reddy's Laboratories Limited",[4],223,false,0,13,18722,[12,15,18,21,24,27,30,33],{"name":13,"count":14},"Healthy",156,{"name":16,"count":17},"Fasting",12,{"name":19,"count":20},"Fed",6,{"name":22,"count":23},"Head Lice Infestation",5,{"name":25,"count":26},"Acne Vulgaris",4,{"name":28,"count":29},"Rheumatoid Arthritis",3,{"name":31,"count":32},"Pediculosis",2,{"name":34,"count":32},"Psoriasis",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,73,91,117,135,162,187,250,298,324,361,395,422,440,458,482,500,524,550,568,592,618,644,671,689,707,731,749,775,793,811,837,855,873,899,917,935,960,978,996,1023,1041,1059,1077,1104,1122,1144,1169,1195,1213,1231,1255,1281,1307,1325,1352,1370,1448,1517,1562,1607,1652,1698,1739,1781,1827,1856,1887,1915,1943,1971,2001,2028,2058,2080,2107,2135,2164,2191,2221,2250,2279,2307,2339,2366,2394,2424,2451,2479,2508,2540,2562,2593,2615,2642,2670,2699,2727,2749,2780,2809,2836,2867,2895,2917,2945,2967,2994,3023,3050,3078,3105,3132,3161,3188,3215,3245,3274,3296,3324,3351,3380,3402,3430,3461,3488,3516,3538,3565,3592,3620,3654,3675,3696,3723,3741,3759,3780,3801,3822,3847,3865,3887,3908,3929,3952,3970,3988,4006,4024,4045,4066,4089,4112,4134,4156,4181,4199,4217,4243,4261,4279,4297,4319,4342,4370,4388,4406,4424,4445,4467,4500,4522,4540],{"intervention":45,"totalTrials":46,"cells":47},"Ketorolac Tromethamine",1,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":71},{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[],{"trials":55,"activeCount":8},[],{"trials":57,"activeCount":8},[58],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":69},"NCT02638831","Ketorol Gel in Gonarthrosis and Low Back Pain","COMPLETED",[41],"2013-11","2013-03",240,[67,68],"Gonarthrosis","Low Back Pain",[45,70],"Ketoprofen",{"trials":72,"activeCount":8},[],{"intervention":70,"totalTrials":46,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":89},{"trials":76,"activeCount":8},[],{"trials":78,"activeCount":8},[],{"trials":80,"activeCount":8},[],{"trials":82,"activeCount":8},[],{"trials":84,"activeCount":8},[85],{"nctId":59,"briefTitle":60,"status":61,"phases":86,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":87,"interventions":88},[41],[67,68],[45,70],{"trials":90,"activeCount":8},[],{"intervention":92,"totalTrials":46,"cells":93},"OMEZ 40",{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":115},{"trials":95,"activeCount":8},[],{"trials":97,"activeCount":8},[],{"trials":99,"activeCount":8},[],{"trials":101,"activeCount":8},[],{"trials":103,"activeCount":8},[104],{"nctId":105,"briefTitle":106,"status":61,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT02922699","Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases",[41],"2013-06","2013-01",120,[112],"GERD",[92,114],"OMEZ 80",{"trials":116,"activeCount":8},[],{"intervention":114,"totalTrials":46,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":133},{"trials":120,"activeCount":8},[],{"trials":122,"activeCount":8},[],{"trials":124,"activeCount":8},[],{"trials":126,"activeCount":8},[],{"trials":128,"activeCount":8},[129],{"nctId":105,"briefTitle":106,"status":61,"phases":130,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":131,"interventions":132},[41],[112],[92,114],{"trials":134,"activeCount":8},[],{"intervention":136,"totalTrials":46,"cells":137},"Panitumumab",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":160},{"trials":139,"activeCount":8},[],{"trials":141,"activeCount":8},[],{"trials":143,"activeCount":8},[],{"trials":145,"activeCount":8},[],{"trials":147,"activeCount":8},[148],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT02301962","Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer","UNKNOWN",[41],"2021-06-30","2022-01-31","2015-07-28",58,[158],"Cancer",[136],{"trials":161,"activeCount":8},[],{"intervention":163,"totalTrials":46,"cells":164},"NISE",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":185},{"trials":166,"activeCount":8},[],{"trials":168,"activeCount":8},[],{"trials":170,"activeCount":8},[],{"trials":172,"activeCount":8},[],{"trials":174,"activeCount":8},[175],{"nctId":176,"briefTitle":177,"status":61,"phases":178,"primaryCompletion":108,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT02922712","Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthrosis)",[41],"2013-08","2011-03",202,[183],"Knee Osteoarthritis",[163],{"trials":186,"activeCount":8},[],{"intervention":188,"totalTrials":23,"cells":189},"Abametapir Lotion 0.74% w\u002Fw",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":215,"PHASE3":227,"PHASE4":246,"NA":248},{"trials":191,"activeCount":8},[],{"trials":193,"activeCount":8},[194,206],{"nctId":195,"briefTitle":196,"status":61,"phases":197,"primaryCompletion":198,"completion":199,"start":198,"enrollment":200,"conditions":201,"interventions":203},"NCT02061813","Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion",[38],"2014-01","2014-05",40,[202],"Head Lice",[188,204,205],"Sodium Lauryl Sulfate","Saline 0.9%",{"nctId":207,"briefTitle":208,"status":61,"phases":209,"primaryCompletion":210,"completion":211,"start":198,"enrollment":212,"conditions":213,"interventions":214},"NCT02062073","Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion",[38],"2014-03","2014-06",238,[202],[188],{"trials":216,"activeCount":8},[217],{"nctId":218,"briefTitle":219,"status":61,"phases":220,"primaryCompletion":221,"completion":222,"start":199,"enrollment":223,"conditions":224,"interventions":225},"NCT02097485","Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation",[39],"2014-09","2014-10",50,[22],[188,226],"Vehicle Lotion",{"trials":228,"activeCount":8},[229,239],{"nctId":230,"briefTitle":231,"status":61,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":238},"NCT02062060","Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation",[40],"2014-07","2014-08","2014-02",325,[22],[188,226],{"nctId":240,"briefTitle":241,"status":61,"phases":242,"primaryCompletion":233,"completion":234,"start":235,"enrollment":243,"conditions":244,"interventions":245},"NCT02060903","A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation",[40],379,[22],[188,226],{"trials":247,"activeCount":8},[],{"trials":249,"activeCount":8},[],{"intervention":251,"totalTrials":29,"cells":252},"DFN-11",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":281,"PHASE4":294,"NA":296},{"trials":254,"activeCount":8},[],{"trials":256,"activeCount":8},[],{"trials":258,"activeCount":8},[259,270],{"nctId":260,"briefTitle":261,"status":61,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NCT02571049","Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine",[39],"2016-04","2016-05","2015-09",24,[268],"Rapidly Escalating Migraine",[251],{"nctId":271,"briefTitle":272,"status":273,"phases":274,"primaryCompletion":275,"completion":276,"start":265,"enrollment":277,"conditions":278,"interventions":280},"NCT02583425","Pilot Study of DFN-11 Injection in Medication Overuse Headache","TERMINATED",[39],"2016-08","2016-11",27,[279],"Medication Overuse Headache",[251],{"trials":282,"activeCount":8},[283],{"nctId":284,"briefTitle":285,"status":61,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT02569853","DFN-11 Injection in Episodic Migraine With or Without Aura",[40],"2017-05-30","2018-02-26","2015-09-21",268,[292],"Episodic Migraine",[251],{"trials":295,"activeCount":8},[],{"trials":297,"activeCount":8},[],{"intervention":226,"totalTrials":29,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":310,"PHASE4":320,"NA":322},{"trials":301,"activeCount":8},[],{"trials":303,"activeCount":8},[],{"trials":305,"activeCount":8},[306],{"nctId":218,"briefTitle":219,"status":61,"phases":307,"primaryCompletion":221,"completion":222,"start":199,"enrollment":223,"conditions":308,"interventions":309},[39],[22],[188,226],{"trials":311,"activeCount":8},[312,316],{"nctId":230,"briefTitle":231,"status":61,"phases":313,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":314,"interventions":315},[40],[22],[188,226],{"nctId":240,"briefTitle":241,"status":61,"phases":317,"primaryCompletion":233,"completion":234,"start":235,"enrollment":243,"conditions":318,"interventions":319},[40],[22],[188,226],{"trials":321,"activeCount":8},[],{"trials":323,"activeCount":8},[],{"intervention":325,"totalTrials":32,"cells":326},"DRL_RI",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":344,"PHASE4":357,"NA":359},{"trials":328,"activeCount":8},[],{"trials":330,"activeCount":8},[],{"trials":332,"activeCount":8},[333],{"nctId":334,"briefTitle":335,"status":61,"phases":336,"primaryCompletion":276,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT02296775","Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis",[38,39],"2017-10-05","2014-11",276,[28],[325,342,343],"Rituxan","MabThera",{"trials":345,"activeCount":8},[346],{"nctId":347,"briefTitle":348,"status":61,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT03976102","Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma",[40],"2022-09-28","2023-02-27","2019-05-15",317,[355],"Follicular Lymphoma",[325],{"trials":358,"activeCount":8},[],{"trials":360,"activeCount":8},[],{"intervention":362,"totalTrials":32,"cells":363},"DFD-03",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":391,"NA":393},{"trials":365,"activeCount":8},[],{"trials":367,"activeCount":8},[],{"trials":369,"activeCount":8},[],{"trials":371,"activeCount":8},[372,381],{"nctId":373,"briefTitle":374,"status":61,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT03290027","A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris",[40],"2018-04-19","2017-07-31",550,[25],[362],{"nctId":382,"briefTitle":383,"status":61,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT03292640","A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks",[40],"2018-05-14","2017-07-06",547,[25],[390,362],"DFD-03 (0.1% tazarotene) Lotion",{"trials":392,"activeCount":8},[],{"trials":394,"activeCount":8},[],{"intervention":396,"totalTrials":46,"cells":397},"Low dose DFD07 once daily",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":418,"NA":420},{"trials":399,"activeCount":8},[],{"trials":401,"activeCount":8},[],{"trials":403,"activeCount":8},[],{"trials":405,"activeCount":8},[406],{"nctId":407,"briefTitle":408,"status":61,"phases":409,"primaryCompletion":410,"completion":411,"start":412,"enrollment":65,"conditions":413,"interventions":415},"NCT03116698","A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and\u002For Scalp Over a 12-week Treatment Period",[39,40],"2017-11-13","2018-07-05","2017-02-14",[414],"Actinic Keratosis (AK)",[396,416,417],"High dose DFD07 once daily","High dose DFD07 twice daily",{"trials":419,"activeCount":8},[],{"trials":421,"activeCount":8},[],{"intervention":416,"totalTrials":46,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":436,"NA":438},{"trials":425,"activeCount":8},[],{"trials":427,"activeCount":8},[],{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[432],{"nctId":407,"briefTitle":408,"status":61,"phases":433,"primaryCompletion":410,"completion":411,"start":412,"enrollment":65,"conditions":434,"interventions":435},[39,40],[414],[396,416,417],{"trials":437,"activeCount":8},[],{"trials":439,"activeCount":8},[],{"intervention":417,"totalTrials":46,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":454,"NA":456},{"trials":443,"activeCount":8},[],{"trials":445,"activeCount":8},[],{"trials":447,"activeCount":8},[],{"trials":449,"activeCount":8},[450],{"nctId":407,"briefTitle":408,"status":61,"phases":451,"primaryCompletion":410,"completion":411,"start":412,"enrollment":65,"conditions":452,"interventions":453},[39,40],[414],[396,416,417],{"trials":455,"activeCount":8},[],{"trials":457,"activeCount":8},[],{"intervention":459,"totalTrials":46,"cells":460},"Lubiprostone",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":478,"NA":480},{"trials":462,"activeCount":8},[],{"trials":464,"activeCount":8},[],{"trials":466,"activeCount":8},[],{"trials":468,"activeCount":8},[469],{"nctId":470,"briefTitle":471,"status":61,"phases":472,"primaryCompletion":198,"completion":210,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT01674530","Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation",[40],"2012-10",909,[476],"Chronic Idiopathic Constipation",[459,459],{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"intervention":390,"totalTrials":46,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":496,"NA":498},{"trials":485,"activeCount":8},[],{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[],{"trials":491,"activeCount":8},[492],{"nctId":382,"briefTitle":383,"status":61,"phases":493,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":494,"interventions":495},[40],[25],[390,362],{"trials":497,"activeCount":8},[],{"trials":499,"activeCount":8},[],{"intervention":501,"totalTrials":46,"cells":502},"DFN-02",{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":520,"NA":522},{"trials":504,"activeCount":8},[],{"trials":506,"activeCount":8},[],{"trials":508,"activeCount":8},[],{"trials":510,"activeCount":8},[511],{"nctId":512,"briefTitle":513,"status":61,"phases":514,"primaryCompletion":265,"completion":515,"start":221,"enrollment":516,"conditions":517,"interventions":519},"NCT02279082","DFN-02 Open Label Safety Study in Patients With Acute Migraine",[40],"2016-03",167,[518],"Acute Migraine",[501],{"trials":521,"activeCount":8},[],{"trials":523,"activeCount":8},[],{"intervention":525,"totalTrials":46,"cells":526},"Experimental: Arm A: DRL_RI",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":546,"NA":548},{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[],{"trials":532,"activeCount":8},[],{"trials":534,"activeCount":8},[535],{"nctId":536,"briefTitle":537,"status":61,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT04268771","A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products",[40],"2022-01-26","2022-04-20","2020-04-08",140,[28],[525,545],"Arm B: Rituxan®\u002FMabthera®",{"trials":547,"activeCount":8},[],{"trials":549,"activeCount":8},[],{"intervention":545,"totalTrials":46,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":564,"NA":566},{"trials":553,"activeCount":8},[],{"trials":555,"activeCount":8},[],{"trials":557,"activeCount":8},[],{"trials":559,"activeCount":8},[560],{"nctId":536,"briefTitle":537,"status":61,"phases":561,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":562,"interventions":563},[40],[28],[525,545],{"trials":565,"activeCount":8},[],{"trials":567,"activeCount":8},[],{"intervention":569,"totalTrials":46,"cells":570},"Permethrin",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":588,"NA":590},{"trials":572,"activeCount":8},[],{"trials":574,"activeCount":8},[],{"trials":576,"activeCount":8},[],{"trials":578,"activeCount":8},[579],{"nctId":580,"briefTitle":581,"status":61,"phases":582,"primaryCompletion":583,"completion":275,"start":265,"enrollment":584,"conditions":585,"interventions":587},"NCT02572986","A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies",[40],"2016-06",250,[586],"Scabies",[569],{"trials":589,"activeCount":8},[],{"trials":591,"activeCount":8},[],{"intervention":593,"totalTrials":46,"cells":594},"AVIGAN",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":614,"NA":616},{"trials":596,"activeCount":8},[],{"trials":598,"activeCount":8},[],{"trials":600,"activeCount":8},[],{"trials":602,"activeCount":8},[603],{"nctId":604,"briefTitle":605,"status":273,"phases":606,"primaryCompletion":607,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT04529499","Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients",[40],"2021-01-22","2021-01-27","2020-08-22",353,[612],"Covid19",[593],{"trials":615,"activeCount":8},[],{"trials":617,"activeCount":8},[],{"intervention":619,"totalTrials":46,"cells":620},"Gam-COVID-Vac",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":640,"NA":642},{"trials":622,"activeCount":8},[],{"trials":624,"activeCount":8},[],{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[629],{"nctId":630,"briefTitle":631,"status":151,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":639},"NCT04640233","Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection",[39,40],"2021-08","2021-09","2020-11-30",1600,[638],"COVID-19 Prevention",[619],{"trials":641,"activeCount":8},[],{"trials":643,"activeCount":8},[],{"intervention":645,"totalTrials":46,"cells":646},"Group A - Low-Dose Ha44 0.37% w\u002Fw",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":648,"activeCount":8},[],{"trials":650,"activeCount":8},[],{"trials":652,"activeCount":8},[653],{"nctId":654,"briefTitle":655,"status":61,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT01336647","An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation",[39],"2011-08","2012-03","2011-04",142,[31],[645,663,664],"Group B - High Dose Ha44 Gel 0.74% w\u002Fw","Group C - Placebo",{"trials":666,"activeCount":8},[],{"trials":668,"activeCount":8},[],{"trials":670,"activeCount":8},[],{"intervention":663,"totalTrials":46,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":683,"PHASE4":685,"NA":687},{"trials":674,"activeCount":8},[],{"trials":676,"activeCount":8},[],{"trials":678,"activeCount":8},[679],{"nctId":654,"briefTitle":655,"status":61,"phases":680,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":681,"interventions":682},[39],[31],[645,663,664],{"trials":684,"activeCount":8},[],{"trials":686,"activeCount":8},[],{"trials":688,"activeCount":8},[],{"intervention":664,"totalTrials":46,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":692,"activeCount":8},[],{"trials":694,"activeCount":8},[],{"trials":696,"activeCount":8},[697],{"nctId":654,"briefTitle":655,"status":61,"phases":698,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":699,"interventions":700},[39],[31],[645,663,664],{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[],{"trials":706,"activeCount":8},[],{"intervention":708,"totalTrials":46,"cells":709},"Tazarotene Lotion, 0.1%",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":711,"activeCount":8},[],{"trials":713,"activeCount":8},[],{"trials":715,"activeCount":8},[716],{"nctId":717,"briefTitle":718,"status":61,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":156,"conditions":722,"interventions":723},"NCT03599193","A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris",[39],"2018-04-30","2017-10-04",[25],[708,724],"Tazarotene Cream, 0.1%",{"trials":726,"activeCount":8},[],{"trials":728,"activeCount":8},[],{"trials":730,"activeCount":8},[],{"intervention":724,"totalTrials":46,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":8},[],{"trials":736,"activeCount":8},[],{"trials":738,"activeCount":8},[739],{"nctId":717,"briefTitle":718,"status":61,"phases":740,"primaryCompletion":720,"completion":720,"start":721,"enrollment":156,"conditions":741,"interventions":742},[39],[25],[708,724],{"trials":744,"activeCount":8},[],{"trials":746,"activeCount":8},[],{"trials":748,"activeCount":8},[],{"intervention":750,"totalTrials":46,"cells":751},"XP23829 400 mg QD",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":753,"activeCount":8},[],{"trials":755,"activeCount":8},[],{"trials":757,"activeCount":8},[758],{"nctId":759,"briefTitle":760,"status":61,"phases":761,"primaryCompletion":762,"completion":763,"start":211,"enrollment":764,"conditions":765,"interventions":766},"NCT02173301","A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis",[39],"2015-05","2015-08",200,[34],[750,767,768],"XP 23829 800 mg QD","XP23829 400 mg BID",{"trials":770,"activeCount":8},[],{"trials":772,"activeCount":8},[],{"trials":774,"activeCount":8},[],{"intervention":767,"totalTrials":46,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":778,"activeCount":8},[],{"trials":780,"activeCount":8},[],{"trials":782,"activeCount":8},[783],{"nctId":759,"briefTitle":760,"status":61,"phases":784,"primaryCompletion":762,"completion":763,"start":211,"enrollment":764,"conditions":785,"interventions":786},[39],[34],[750,767,768],{"trials":788,"activeCount":8},[],{"trials":790,"activeCount":8},[],{"trials":792,"activeCount":8},[],{"intervention":768,"totalTrials":46,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":796,"activeCount":8},[],{"trials":798,"activeCount":8},[],{"trials":800,"activeCount":8},[801],{"nctId":759,"briefTitle":760,"status":61,"phases":802,"primaryCompletion":762,"completion":763,"start":211,"enrollment":764,"conditions":803,"interventions":804},[39],[34],[750,767,768],{"trials":806,"activeCount":8},[],{"trials":808,"activeCount":8},[],{"trials":810,"activeCount":8},[],{"intervention":812,"totalTrials":46,"cells":813},"Metronidazole",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":815,"activeCount":8},[],{"trials":817,"activeCount":8},[],{"trials":819,"activeCount":8},[820],{"nctId":821,"briefTitle":822,"status":61,"phases":823,"primaryCompletion":824,"completion":64,"start":658,"enrollment":825,"conditions":826,"interventions":828},"NCT01559545","A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis",[39],"2013-02",60,[827],"Clostridium Difficile Associated Diarrhea",[812,829,830],"Metronidazole-DRF1","Metronidazole-DRF2",{"trials":832,"activeCount":8},[],{"trials":834,"activeCount":8},[],{"trials":836,"activeCount":8},[],{"intervention":829,"totalTrials":46,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":8},[],{"trials":842,"activeCount":8},[],{"trials":844,"activeCount":8},[845],{"nctId":821,"briefTitle":822,"status":61,"phases":846,"primaryCompletion":824,"completion":64,"start":658,"enrollment":825,"conditions":847,"interventions":848},[39],[827],[812,829,830],{"trials":850,"activeCount":8},[],{"trials":852,"activeCount":8},[],{"trials":854,"activeCount":8},[],{"intervention":830,"totalTrials":46,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":858,"activeCount":8},[],{"trials":860,"activeCount":8},[],{"trials":862,"activeCount":8},[863],{"nctId":821,"briefTitle":822,"status":61,"phases":864,"primaryCompletion":824,"completion":64,"start":658,"enrollment":825,"conditions":865,"interventions":866},[39],[827],[812,829,830],{"trials":868,"activeCount":8},[],{"trials":870,"activeCount":8},[],{"trials":872,"activeCount":8},[],{"intervention":874,"totalTrials":46,"cells":875},"DFN-15 (Celecoxib Oral Solution) 62.5 mg",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":877,"activeCount":8},[],{"trials":879,"activeCount":8},[],{"trials":881,"activeCount":8},[882],{"nctId":883,"briefTitle":884,"status":61,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":110,"conditions":888,"interventions":890},"NCT03554772","Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15",[39],"2018-08-20","2018-06-19",[889],"Acute Pain",[874,891,892],"DFN-15 (Celecoxib Oral Solution) 125 mg","DFN-15 (Celecoxib Oral Solution) 250 mg",{"trials":894,"activeCount":8},[],{"trials":896,"activeCount":8},[],{"trials":898,"activeCount":8},[],{"intervention":891,"totalTrials":46,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":902,"activeCount":8},[],{"trials":904,"activeCount":8},[],{"trials":906,"activeCount":8},[907],{"nctId":883,"briefTitle":884,"status":61,"phases":908,"primaryCompletion":886,"completion":886,"start":887,"enrollment":110,"conditions":909,"interventions":910},[39],[889],[874,891,892],{"trials":912,"activeCount":8},[],{"trials":914,"activeCount":8},[],{"trials":916,"activeCount":8},[],{"intervention":892,"totalTrials":46,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":920,"activeCount":8},[],{"trials":922,"activeCount":8},[],{"trials":924,"activeCount":8},[925],{"nctId":883,"briefTitle":884,"status":61,"phases":926,"primaryCompletion":886,"completion":886,"start":887,"enrollment":110,"conditions":927,"interventions":928},[39],[889],[874,891,892],{"trials":930,"activeCount":8},[],{"trials":932,"activeCount":8},[],{"trials":934,"activeCount":8},[],{"intervention":936,"totalTrials":46,"cells":937},"DFA-02",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":939,"activeCount":8},[],{"trials":941,"activeCount":8},[],{"trials":943,"activeCount":8},[944],{"nctId":945,"briefTitle":946,"status":61,"phases":947,"primaryCompletion":948,"completion":108,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT01496352","DFA-02 in Patients Undergoing Colorectal Surgery",[38,39],"2013-04","2012-02",30,[952],"Surgical Site Infection",[936],{"trials":955,"activeCount":8},[],{"trials":957,"activeCount":8},[],{"trials":959,"activeCount":8},[],{"intervention":342,"totalTrials":46,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":963,"activeCount":8},[],{"trials":965,"activeCount":8},[],{"trials":967,"activeCount":8},[968],{"nctId":334,"briefTitle":335,"status":61,"phases":969,"primaryCompletion":276,"completion":337,"start":338,"enrollment":339,"conditions":970,"interventions":971},[38,39],[28],[325,342,343],{"trials":973,"activeCount":8},[],{"trials":975,"activeCount":8},[],{"trials":977,"activeCount":8},[],{"intervention":343,"totalTrials":46,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":981,"activeCount":8},[],{"trials":983,"activeCount":8},[],{"trials":985,"activeCount":8},[986],{"nctId":334,"briefTitle":335,"status":61,"phases":987,"primaryCompletion":276,"completion":337,"start":338,"enrollment":339,"conditions":988,"interventions":989},[38,39],[28],[325,342,343],{"trials":991,"activeCount":8},[],{"trials":993,"activeCount":8},[],{"trials":995,"activeCount":8},[],{"intervention":997,"totalTrials":46,"cells":998},"DFD-03 Lotion, 0.1%",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1000,"activeCount":8},[],{"trials":1002,"activeCount":8},[],{"trials":1004,"activeCount":8},[1005],{"nctId":1006,"briefTitle":1007,"status":61,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT03341910","A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris",[39],"2018-05-18","2017-08-21",155,[25],[997,1014,1015,1016],"Tazorac Cream, 0.1%","DFD-03 Vehicle Lotion 0%","Tazorac Vehicle Cream 0%",{"trials":1018,"activeCount":8},[],{"trials":1020,"activeCount":8},[],{"trials":1022,"activeCount":8},[],{"intervention":1014,"totalTrials":46,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":8},[],{"trials":1028,"activeCount":8},[],{"trials":1030,"activeCount":8},[1031],{"nctId":1006,"briefTitle":1007,"status":61,"phases":1032,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1033,"interventions":1034},[39],[25],[997,1014,1015,1016],{"trials":1036,"activeCount":8},[],{"trials":1038,"activeCount":8},[],{"trials":1040,"activeCount":8},[],{"intervention":1015,"totalTrials":46,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":8},[],{"trials":1046,"activeCount":8},[],{"trials":1048,"activeCount":8},[1049],{"nctId":1006,"briefTitle":1007,"status":61,"phases":1050,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1051,"interventions":1052},[39],[25],[997,1014,1015,1016],{"trials":1054,"activeCount":8},[],{"trials":1056,"activeCount":8},[],{"trials":1058,"activeCount":8},[],{"intervention":1016,"totalTrials":46,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":8},[],{"trials":1064,"activeCount":8},[],{"trials":1066,"activeCount":8},[1067],{"nctId":1006,"briefTitle":1007,"status":61,"phases":1068,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1069,"interventions":1070},[39],[25],[997,1014,1015,1016],{"trials":1072,"activeCount":8},[],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[],{"intervention":1078,"totalTrials":46,"cells":1079},"DFD-29 Extended Release",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1081,"activeCount":8},[],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[1086],{"nctId":1087,"briefTitle":1088,"status":61,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1096},"NCT03340961","A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules",[39],"2018-11-07","2019-03-31","2017-10-01",205,[1095],"Rosacea",[1078,1078,1097],"Oraycea® (doxycycline)",{"trials":1099,"activeCount":8},[],{"trials":1101,"activeCount":8},[],{"trials":1103,"activeCount":8},[],{"intervention":1097,"totalTrials":46,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1107,"activeCount":8},[],{"trials":1109,"activeCount":8},[],{"trials":1111,"activeCount":8},[1112],{"nctId":1087,"briefTitle":1088,"status":61,"phases":1113,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1114,"interventions":1115},[39],[1095],[1078,1078,1097],{"trials":1117,"activeCount":8},[],{"trials":1119,"activeCount":8},[],{"trials":1121,"activeCount":8},[],{"intervention":1123,"totalTrials":46,"cells":1124},"Ha44 Gel 0.74% w\u002Fw",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1126,"activeCount":8},[],{"trials":1128,"activeCount":8},[],{"trials":1130,"activeCount":8},[1131],{"nctId":1132,"briefTitle":1133,"status":61,"phases":1134,"primaryCompletion":233,"completion":234,"start":948,"enrollment":1135,"conditions":1136,"interventions":1137},"NCT02010333","A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation",[39],22,[22],[1123],{"trials":1139,"activeCount":8},[],{"trials":1141,"activeCount":8},[],{"trials":1143,"activeCount":8},[],{"intervention":1145,"totalTrials":46,"cells":1146},"DFD-04 Ointment",{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1148,"activeCount":8},[],{"trials":1150,"activeCount":8},[],{"trials":1152,"activeCount":8},[1153],{"nctId":1154,"briefTitle":1155,"status":61,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1162},"NCT02828241","A Study to Assess the Efficacy, Safety and Tolerability of DFD-04",[39],"2017-01","2017-11","2016-07",61,[1095],[1145],{"trials":1164,"activeCount":8},[],{"trials":1166,"activeCount":8},[],{"trials":1168,"activeCount":8},[],{"intervention":1170,"totalTrials":46,"cells":1171},"PPC-06 400 mg QD",{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1173,"activeCount":8},[],{"trials":1175,"activeCount":8},[],{"trials":1177,"activeCount":8},[1178],{"nctId":1179,"briefTitle":1180,"status":61,"phases":1181,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT03421197","A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)",[39],"2020-03-30","2018-01-25",426,[34],[1170,1187,1188],"PPC-06 400 mg BID","PPC-06 600 mg",{"trials":1190,"activeCount":8},[],{"trials":1192,"activeCount":8},[],{"trials":1194,"activeCount":8},[],{"intervention":1187,"totalTrials":46,"cells":1196},{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1201,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1198,"activeCount":8},[],{"trials":1200,"activeCount":8},[],{"trials":1202,"activeCount":8},[1203],{"nctId":1179,"briefTitle":1180,"status":61,"phases":1204,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1205,"interventions":1206},[39],[34],[1170,1187,1188],{"trials":1208,"activeCount":8},[],{"trials":1210,"activeCount":8},[],{"trials":1212,"activeCount":8},[],{"intervention":1188,"totalTrials":46,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1216,"activeCount":8},[],{"trials":1218,"activeCount":8},[],{"trials":1220,"activeCount":8},[1221],{"nctId":1179,"briefTitle":1180,"status":61,"phases":1222,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1223,"interventions":1224},[39],[34],[1170,1187,1188],{"trials":1226,"activeCount":8},[],{"trials":1228,"activeCount":8},[],{"trials":1230,"activeCount":8},[],{"intervention":1232,"totalTrials":46,"cells":1233},"Ha44 Gel",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1249,"PHASE4":1251,"NA":1253},{"trials":1235,"activeCount":8},[],{"trials":1237,"activeCount":8},[],{"trials":1239,"activeCount":8},[1240],{"nctId":1241,"briefTitle":1242,"status":61,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":64,"enrollment":1246,"conditions":1247,"interventions":1248},"NCT01907490","Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation",[39],"2013-07","2013-12",38,[22],[1232],{"trials":1250,"activeCount":8},[],{"trials":1252,"activeCount":8},[],{"trials":1254,"activeCount":8},[],{"intervention":1256,"totalTrials":46,"cells":1257},"DRL-17822 or placebo",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1259,"activeCount":8},[],{"trials":1261,"activeCount":8},[],{"trials":1263,"activeCount":8},[1264],{"nctId":1265,"briefTitle":1266,"status":61,"phases":1267,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1274},"NCT01388816","A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels",[39],"2012-05","2012-06","2011-07",176,[1273],"Type II Hyperlipidemia",[1256],{"trials":1276,"activeCount":8},[],{"trials":1278,"activeCount":8},[],{"trials":1280,"activeCount":8},[],{"intervention":1282,"totalTrials":46,"cells":1283},"DFA-02 Antibiotic Gel",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1285,"activeCount":8},[],{"trials":1287,"activeCount":8},[],{"trials":1289,"activeCount":8},[1290],{"nctId":1291,"briefTitle":1292,"status":61,"phases":1293,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1299},"NCT01888367","Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery",[39],"2015-02","2013-10",445,[1298],"Surgical Site Infections",[1282,1300],"DFA-02 Placebo Gel",{"trials":1302,"activeCount":8},[],{"trials":1304,"activeCount":8},[],{"trials":1306,"activeCount":8},[],{"intervention":1300,"totalTrials":46,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":8},[],{"trials":1312,"activeCount":8},[],{"trials":1314,"activeCount":8},[1315],{"nctId":1291,"briefTitle":1292,"status":61,"phases":1316,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":1317,"interventions":1318},[39],[1298],[1282,1300],{"trials":1320,"activeCount":8},[],{"trials":1322,"activeCount":8},[],{"trials":1324,"activeCount":8},[],{"intervention":1326,"totalTrials":46,"cells":1327},"DFN-15 Dose A",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1329,"activeCount":8},[],{"trials":1331,"activeCount":8},[],{"trials":1333,"activeCount":8},[1334],{"nctId":1335,"briefTitle":1336,"status":61,"phases":1337,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1344},"NCT02472418","Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches",[39],"2015-12-01","2016-05-05","2015-06-05",63,[1343],"Migraine",[1326,1345],"DFN-15 Dose B",{"trials":1347,"activeCount":8},[],{"trials":1349,"activeCount":8},[],{"trials":1351,"activeCount":8},[],{"intervention":1345,"totalTrials":46,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":8},[],{"trials":1357,"activeCount":8},[],{"trials":1359,"activeCount":8},[1360],{"nctId":1335,"briefTitle":1336,"status":61,"phases":1361,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1362,"interventions":1363},[39],[1343],[1326,1345],{"trials":1365,"activeCount":8},[],{"trials":1367,"activeCount":8},[],{"trials":1369,"activeCount":8},[],{"intervention":1371,"totalTrials":1372,"cells":1373},"Lamotrigine",8,{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1375,"activeCount":8},[],{"trials":1377,"activeCount":8},[1378,1388,1397,1405,1411,1417,1426,1433],{"nctId":1379,"briefTitle":1380,"status":61,"phases":1381,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1387},"NCT01131949","Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition",[38],"2003-02","2003-03","2003-01",26,[13],[1371],{"nctId":1389,"briefTitle":1390,"status":61,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1392,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT01888757","Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition",[38],"2010-09","2010-10",62,[13],[1371],{"nctId":1398,"briefTitle":1399,"status":61,"phases":1400,"primaryCompletion":1401,"completion":1392,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1404},"NCT01888263","Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition",[38],"2010-08",32,[13],[1371],{"nctId":1406,"briefTitle":1407,"status":61,"phases":1408,"primaryCompletion":1401,"completion":1392,"start":1401,"enrollment":1394,"conditions":1409,"interventions":1410},"NCT01888731","Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition",[38],[13],[1371],{"nctId":1412,"briefTitle":1413,"status":61,"phases":1414,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1415,"interventions":1416},"NCT01131975","Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition",[38],[13],[1371],{"nctId":1418,"briefTitle":1419,"status":61,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1424},"NCT01513720","Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition",[38],"2002-12",20,[13],[1371,1425],"Lamictal®",{"nctId":1427,"briefTitle":1428,"status":61,"phases":1429,"primaryCompletion":1401,"completion":1392,"start":1401,"enrollment":1430,"conditions":1431,"interventions":1432},"NCT01888250","Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition",[38],36,[13],[1371],{"nctId":1434,"briefTitle":1435,"status":61,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1437,"enrollment":1422,"conditions":1438,"interventions":1439},"NCT01513681","Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition",[38],"2002-11",[13],[1371,1425],{"trials":1441,"activeCount":8},[],{"trials":1443,"activeCount":8},[],{"trials":1445,"activeCount":8},[],{"trials":1447,"activeCount":8},[],{"intervention":1449,"totalTrials":1450,"cells":1451},"Divalproex Sodium",7,{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1453,"activeCount":8},[],{"trials":1455,"activeCount":8},[1456,1465,1475,1484,1491,1497,1503],{"nctId":1457,"briefTitle":1458,"status":61,"phases":1459,"primaryCompletion":1460,"completion":180,"start":1461,"enrollment":1462,"conditions":1463,"interventions":1464},"NCT01581788","Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions",[38],"2011-02","2011-01",54,[13],[1449],{"nctId":1466,"briefTitle":1467,"status":61,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT01132170","Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions",[38],"2006-09","2006-11","2006-08",34,[13],[1449],{"nctId":1476,"briefTitle":1477,"status":61,"phases":1478,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1472,"conditions":1482,"interventions":1483},"NCT01056627","Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition",[38],"2007-01","2007-03","2006-12",[13],[1449],{"nctId":1485,"briefTitle":1486,"status":61,"phases":1487,"primaryCompletion":1480,"completion":1480,"start":1488,"enrollment":1472,"conditions":1489,"interventions":1490},"NCT01132183","Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)",[38],"2007-02",[13],[1449],{"nctId":1492,"briefTitle":1493,"status":61,"phases":1494,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1472,"conditions":1495,"interventions":1496},"NCT01055938","Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions",[38],[13],[1449],{"nctId":1498,"briefTitle":1499,"status":61,"phases":1500,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1501,"interventions":1502},"NCT01132196","Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions",[38],[13],[1449],{"nctId":1504,"briefTitle":1505,"status":61,"phases":1506,"primaryCompletion":1461,"completion":180,"start":1461,"enrollment":1462,"conditions":1507,"interventions":1508},"NCT01581775","Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions",[38],[13],[1449],{"trials":1510,"activeCount":8},[],{"trials":1512,"activeCount":8},[],{"trials":1514,"activeCount":8},[],{"trials":1516,"activeCount":8},[],{"intervention":1518,"totalTrials":26,"cells":1519},"Clopidogrel",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1521,"activeCount":8},[],{"trials":1523,"activeCount":8},[1524,1532,1539,1547],{"nctId":1525,"briefTitle":1526,"status":61,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT01512485","Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions",[38],"2006-10",51,[13],[1518],{"nctId":1533,"briefTitle":1534,"status":61,"phases":1535,"primaryCompletion":1469,"completion":1469,"start":1469,"enrollment":1536,"conditions":1537,"interventions":1538},"NCT01506713","Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions",[38],53,[16],[1518],{"nctId":1540,"briefTitle":1541,"status":61,"phases":1542,"primaryCompletion":1543,"completion":1543,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT01621763","Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions",[38],"2008-09",68,[13],[1518],{"nctId":1548,"briefTitle":1549,"status":61,"phases":1550,"primaryCompletion":1543,"completion":1543,"start":1551,"enrollment":1544,"conditions":1552,"interventions":1553},"NCT01621750","Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions",[38],"2008-08",[16],[1518],{"trials":1555,"activeCount":8},[],{"trials":1557,"activeCount":8},[],{"trials":1559,"activeCount":8},[],{"trials":1561,"activeCount":8},[],{"intervention":1563,"totalTrials":26,"cells":1564},"Montelukast sodium",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1566,"activeCount":8},[],{"trials":1568,"activeCount":8},[1569,1578,1585,1592],{"nctId":1570,"briefTitle":1571,"status":61,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1577},"NCT01671722","Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed Condition",[38],"2010-03","2010-02",43,[13],[1563],{"nctId":1579,"briefTitle":1580,"status":61,"phases":1581,"primaryCompletion":1461,"completion":1460,"start":1461,"enrollment":1582,"conditions":1583,"interventions":1584},"NCT01691469","Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition",[38],31,[13],[1563],{"nctId":1586,"briefTitle":1587,"status":61,"phases":1588,"primaryCompletion":1461,"completion":1460,"start":1461,"enrollment":1589,"conditions":1590,"interventions":1591},"NCT01691456","Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fasting Condition",[38],45,[13],[1563],{"nctId":1593,"briefTitle":1594,"status":61,"phases":1595,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":1596,"conditions":1597,"interventions":1598},"NCT01671709","Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fasting Condition",[38],41,[13],[1563],{"trials":1600,"activeCount":8},[],{"trials":1602,"activeCount":8},[],{"trials":1604,"activeCount":8},[],{"trials":1606,"activeCount":8},[],{"intervention":1608,"totalTrials":26,"cells":1609},"Desloratadine",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1611,"activeCount":8},[],{"trials":1613,"activeCount":8},[1614,1623,1630,1638],{"nctId":1615,"briefTitle":1616,"status":61,"phases":1617,"primaryCompletion":1618,"completion":1619,"start":1618,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT01314339","Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.",[38],"2005-12","2006-02",28,[16],[1608],{"nctId":1624,"briefTitle":1625,"status":61,"phases":1626,"primaryCompletion":1618,"completion":1627,"start":1618,"enrollment":1620,"conditions":1628,"interventions":1629},"NCT01314352","Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions",[38],"2006-03",[19],[1608],{"nctId":1631,"briefTitle":1632,"status":61,"phases":1633,"completion":1619,"start":1634,"enrollment":1635,"conditions":1636,"interventions":1637},"NCT01506050","Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition",[38],"2006-01",35,[13],[1608],{"nctId":1639,"briefTitle":1640,"status":61,"phases":1641,"completion":1619,"start":1634,"enrollment":1430,"conditions":1642,"interventions":1643},"NCT01506037","Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition",[38],[13],[1608],{"trials":1645,"activeCount":8},[],{"trials":1647,"activeCount":8},[],{"trials":1649,"activeCount":8},[],{"trials":1651,"activeCount":8},[],{"intervention":1653,"totalTrials":26,"cells":1654},"Isotretinoin",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1656,"activeCount":8},[],{"trials":1658,"activeCount":8},[1659,1666,1675,1682],{"nctId":1660,"briefTitle":1661,"status":61,"phases":1662,"primaryCompletion":1663,"completion":1270,"start":1663,"enrollment":1160,"conditions":1664,"interventions":1665},"NCT01888224","Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition",[38],"2011-06",[13],[1653],{"nctId":1667,"briefTitle":1668,"status":61,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1635,"conditions":1673,"interventions":1674},"NCT01888289","Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition",[38],"2001-08","2001-09","2001-07",[13],[1653],{"nctId":1676,"briefTitle":1677,"status":61,"phases":1678,"primaryCompletion":1679,"completion":1679,"start":1679,"enrollment":1596,"conditions":1680,"interventions":1681},"NCT01888341","Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition",[38],"2002-08",[13],[1653],{"nctId":1683,"briefTitle":1684,"status":61,"phases":1685,"primaryCompletion":1686,"completion":1687,"start":1686,"enrollment":1385,"conditions":1688,"interventions":1689},"NCT01888328","Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition",[38],"2001-05","2001-06",[13],[1653],{"trials":1691,"activeCount":8},[],{"trials":1693,"activeCount":8},[],{"trials":1695,"activeCount":8},[],{"trials":1697,"activeCount":8},[],{"intervention":1699,"totalTrials":26,"cells":1700},"Finasteride",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1702,"activeCount":8},[],{"trials":1704,"activeCount":8},[1705,1711,1719,1725],{"nctId":1706,"briefTitle":1707,"status":61,"phases":1708,"primaryCompletion":1470,"completion":1470,"start":1470,"enrollment":1385,"conditions":1709,"interventions":1710},"NCT01264302","Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions",[38],[13],[1699],{"nctId":1712,"briefTitle":1713,"status":61,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1715,"enrollment":266,"conditions":1717,"interventions":1718},"NCT01133444","Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition",[38],"2002-04","2002-05",[13],[1699],{"nctId":1720,"briefTitle":1721,"status":61,"phases":1722,"primaryCompletion":1716,"completion":1716,"start":1715,"enrollment":266,"conditions":1723,"interventions":1724},"NCT01133457","Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition",[38],[13],[1699],{"nctId":1726,"briefTitle":1727,"status":61,"phases":1728,"primaryCompletion":1470,"completion":1470,"start":1470,"enrollment":1385,"conditions":1729,"interventions":1730},"NCT01264289","Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions",[38],[13],[1699],{"trials":1732,"activeCount":8},[],{"trials":1734,"activeCount":8},[],{"trials":1736,"activeCount":8},[],{"trials":1738,"activeCount":8},[],{"intervention":1740,"totalTrials":26,"cells":1741},"Omeprazole",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1743,"activeCount":8},[],{"trials":1745,"activeCount":8},[1746,1753,1761,1767],{"nctId":1747,"briefTitle":1748,"status":61,"phases":1749,"primaryCompletion":1750,"completion":1750,"start":1619,"enrollment":1462,"conditions":1751,"interventions":1752},"NCT01170182","Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition",[38],"2006-04",[13],[1740],{"nctId":1754,"briefTitle":1755,"status":61,"phases":1756,"primaryCompletion":1627,"completion":1627,"start":1634,"enrollment":1757,"conditions":1758,"interventions":1759},"NCT01170169","Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions",[38],44,[13],[1740,1760],"Prilosec",{"nctId":1762,"briefTitle":1763,"status":61,"phases":1764,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1394,"conditions":1765,"interventions":1766},"NCT01045434","Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions",[38],[13],[1740],{"nctId":1768,"briefTitle":1769,"status":61,"phases":1770,"primaryCompletion":1481,"completion":1480,"start":1481,"enrollment":1246,"conditions":1771,"interventions":1772},"NCT01045642","Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions",[38],[13],[1740],{"trials":1774,"activeCount":8},[],{"trials":1776,"activeCount":8},[],{"trials":1778,"activeCount":8},[],{"trials":1780,"activeCount":8},[],{"intervention":1782,"totalTrials":26,"cells":1783},"Mycophenolate Mofetil",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1785,"activeCount":8},[],{"trials":1787,"activeCount":8},[1788,1796,1805,1813],{"nctId":1789,"briefTitle":1790,"status":61,"phases":1791,"primaryCompletion":1792,"completion":1793,"start":1792,"enrollment":1160,"conditions":1794,"interventions":1795},"NCT01513057","Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions",[38],"2009-01","2009-02",[13],[1782,1782],{"nctId":1797,"briefTitle":1798,"status":61,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1804},"NCT01283841","Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting Conditions",[38],"2007-12","2007-11",48,[16],[1782],{"nctId":1806,"briefTitle":1807,"status":61,"phases":1808,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT01283867","Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions",[38],92,[1811],"FED",[1782],{"nctId":1814,"briefTitle":1815,"status":61,"phases":1816,"primaryCompletion":1792,"completion":1792,"start":1792,"enrollment":1544,"conditions":1817,"interventions":1818},"NCT01513044","Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting Conditions",[38],[13],[1782,1782],{"trials":1820,"activeCount":8},[],{"trials":1822,"activeCount":8},[],{"trials":1824,"activeCount":8},[],{"trials":1826,"activeCount":8},[],{"intervention":1828,"totalTrials":32,"cells":1829},"Eszopiclone Tablets 3 mg",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1831,"activeCount":8},[],{"trials":1833,"activeCount":8},[1834,1842],{"nctId":1835,"briefTitle":1836,"status":61,"phases":1837,"primaryCompletion":1543,"completion":1838,"start":1543,"enrollment":1839,"conditions":1840,"interventions":1841},"NCT02322658","Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions",[38],"2008-10",46,[13],[1828],{"nctId":1843,"briefTitle":1844,"status":61,"phases":1845,"primaryCompletion":1551,"completion":1838,"start":1551,"enrollment":1839,"conditions":1846,"interventions":1847},"NCT02322645","Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions",[38],[13],[1828],{"trials":1849,"activeCount":8},[],{"trials":1851,"activeCount":8},[],{"trials":1853,"activeCount":8},[],{"trials":1855,"activeCount":8},[],{"intervention":1857,"totalTrials":32,"cells":1858},"Amlodipine Besylate \u002F Benazepril Hydrochloride",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1860,"activeCount":8},[],{"trials":1862,"activeCount":8},[1863,1871],{"nctId":1864,"briefTitle":1865,"status":61,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1802,"conditions":1869,"interventions":1870},"NCT01155908","Bioequivalence Study of 10 mg Amlodipine Besylate\u002F 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions",[38],"2005-05","2005-04",[13],[1857],{"nctId":1872,"briefTitle":1873,"status":61,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1875,"enrollment":1462,"conditions":1877,"interventions":1878},"NCT01155895","Bioequivalence Study of 10 mg Amlodipine Besylate\u002F 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions",[38],"2004-03","2004-04",[13],[1857],{"trials":1880,"activeCount":8},[],{"trials":1882,"activeCount":8},[],{"trials":1884,"activeCount":8},[],{"trials":1886,"activeCount":8},[],{"intervention":1888,"totalTrials":32,"cells":1889},"Risperidone Orally Disintegrating",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[1894,1901],{"nctId":1895,"briefTitle":1896,"status":61,"phases":1897,"primaryCompletion":1898,"completion":1898,"start":1898,"enrollment":1430,"conditions":1899,"interventions":1900},"NCT01155934","Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions",[38],"2004-08",[13],[1888],{"nctId":1902,"briefTitle":1903,"status":61,"phases":1904,"primaryCompletion":1898,"completion":1898,"start":1898,"enrollment":1430,"conditions":1905,"interventions":1906},"NCT01155921","Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions",[38],[13],[1888],{"trials":1908,"activeCount":8},[],{"trials":1910,"activeCount":8},[],{"trials":1912,"activeCount":8},[],{"trials":1914,"activeCount":8},[],{"intervention":1916,"totalTrials":32,"cells":1917},"Nateglinide",{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1919,"activeCount":8},[],{"trials":1921,"activeCount":8},[1922,1928],{"nctId":1923,"briefTitle":1924,"status":61,"phases":1925,"primaryCompletion":1488,"completion":1488,"start":1488,"enrollment":1544,"conditions":1926,"interventions":1927},"NCT01159158","Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition",[38],[13],[1916],{"nctId":1929,"briefTitle":1930,"status":61,"phases":1931,"primaryCompletion":1932,"completion":1932,"start":1932,"enrollment":156,"conditions":1933,"interventions":1934},"NCT01160029","Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition",[38],"2004-10",[13],[1916],{"trials":1936,"activeCount":8},[],{"trials":1938,"activeCount":8},[],{"trials":1940,"activeCount":8},[],{"trials":1942,"activeCount":8},[],{"intervention":1944,"totalTrials":32,"cells":1945},"Metoprolol Succinate",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1947,"activeCount":8},[],{"trials":1949,"activeCount":8},[1950,1956],{"nctId":1951,"briefTitle":1952,"status":61,"phases":1953,"primaryCompletion":1461,"completion":1461,"start":1461,"enrollment":1802,"conditions":1954,"interventions":1955},"NCT01694797","Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition",[38],[13],[1944],{"nctId":1957,"briefTitle":1958,"status":61,"phases":1959,"primaryCompletion":1461,"completion":1461,"start":1960,"enrollment":1802,"conditions":1961,"interventions":1962},"NCT01673997","Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions",[38],"2010-12",[13],[1944],{"trials":1964,"activeCount":8},[],{"trials":1966,"activeCount":8},[],{"trials":1968,"activeCount":8},[],{"trials":1970,"activeCount":8},[],{"intervention":1972,"totalTrials":32,"cells":1973},"Tacrolimus",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1975,"activeCount":8},[],{"trials":1977,"activeCount":8},[1978,1987],{"nctId":1979,"briefTitle":1980,"status":61,"phases":1981,"primaryCompletion":1982,"completion":1983,"start":1984,"enrollment":200,"conditions":1985,"interventions":1986},"NCT01131988","Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddy's Under Fasting Conditions",[38],"2008-02","2008-03","2008-01",[13],[1972],{"nctId":1988,"briefTitle":1989,"status":61,"phases":1990,"primaryCompletion":1982,"completion":1983,"start":1984,"enrollment":200,"conditions":1991,"interventions":1992},"NCT01132027","Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddys's Laboratories Limited Under Non-Fasting Conditions",[38],[13],[1972],{"trials":1994,"activeCount":8},[],{"trials":1996,"activeCount":8},[],{"trials":1998,"activeCount":8},[],{"trials":2000,"activeCount":8},[],{"intervention":2002,"totalTrials":32,"cells":2003},"Risperidone",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2026},{"trials":2005,"activeCount":8},[],{"trials":2007,"activeCount":8},[2008,2014],{"nctId":2009,"briefTitle":2010,"status":61,"phases":2011,"primaryCompletion":1528,"completion":1528,"start":1528,"enrollment":950,"conditions":2012,"interventions":2013},"NCT01064232","Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition",[38],[13],[2002],{"nctId":2015,"briefTitle":2016,"status":61,"phases":2017,"primaryCompletion":1528,"completion":1528,"start":1528,"enrollment":1385,"conditions":2018,"interventions":2019},"NCT01064271","Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition",[38],[13],[2002],{"trials":2021,"activeCount":8},[],{"trials":2023,"activeCount":8},[],{"trials":2025,"activeCount":8},[],{"trials":2027,"activeCount":8},[],{"intervention":2029,"totalTrials":32,"cells":2030},"Duloxetine",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2056},{"trials":2032,"activeCount":8},[],{"trials":2034,"activeCount":8},[2035,2044],{"nctId":2036,"briefTitle":2037,"status":61,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2042},"NCT02291341","Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition",[38],"2008-05",76,[13],[2029,2043],"Cymbalta®",{"nctId":2045,"briefTitle":2046,"status":61,"phases":2047,"primaryCompletion":2039,"completion":2039,"start":2039,"enrollment":2040,"conditions":2048,"interventions":2049},"NCT02291367","Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition",[38],[13],[2029,2043],{"trials":2051,"activeCount":8},[],{"trials":2053,"activeCount":8},[],{"trials":2055,"activeCount":8},[],{"trials":2057,"activeCount":8},[],{"intervention":2043,"totalTrials":32,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2061,"activeCount":8},[],{"trials":2063,"activeCount":8},[2064,2068],{"nctId":2036,"briefTitle":2037,"status":61,"phases":2065,"primaryCompletion":2039,"completion":2039,"start":2039,"enrollment":2040,"conditions":2066,"interventions":2067},[38],[13],[2029,2043],{"nctId":2045,"briefTitle":2046,"status":61,"phases":2069,"primaryCompletion":2039,"completion":2039,"start":2039,"enrollment":2040,"conditions":2070,"interventions":2071},[38],[13],[2029,2043],{"trials":2073,"activeCount":8},[],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[],{"trials":2079,"activeCount":8},[],{"intervention":2081,"totalTrials":32,"cells":2082},"Carvedilol",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2084,"activeCount":8},[],{"trials":2086,"activeCount":8},[2087,2093],{"nctId":2088,"briefTitle":2089,"status":61,"phases":2090,"primaryCompletion":1716,"completion":1716,"start":1716,"enrollment":266,"conditions":2091,"interventions":2092},"NCT01064180","Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions",[38],[13],[2081],{"nctId":2094,"briefTitle":2095,"status":61,"phases":2096,"primaryCompletion":1716,"completion":1716,"start":1716,"enrollment":1430,"conditions":2097,"interventions":2098},"NCT01064154","Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions",[38],[13],[2081],{"trials":2100,"activeCount":8},[],{"trials":2102,"activeCount":8},[],{"trials":2104,"activeCount":8},[],{"trials":2106,"activeCount":8},[],{"intervention":2108,"totalTrials":32,"cells":2109},"Levocetirizine DiHCl",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2127,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2111,"activeCount":8},[],{"trials":2113,"activeCount":8},[2114,2121],{"nctId":2115,"briefTitle":2116,"status":61,"phases":2117,"primaryCompletion":1984,"completion":1984,"start":1800,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT01506076","Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions",[38],29,[16],[2108],{"nctId":2122,"briefTitle":2123,"status":61,"phases":2124,"primaryCompletion":1984,"completion":1984,"start":1984,"enrollment":1582,"conditions":2125,"interventions":2126},"NCT01506063","Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions",[38],[13],[2108],{"trials":2128,"activeCount":8},[],{"trials":2130,"activeCount":8},[],{"trials":2132,"activeCount":8},[],{"trials":2134,"activeCount":8},[],{"intervention":2136,"totalTrials":32,"cells":2137},"Citalopram Hydrobromide",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2139,"activeCount":8},[],{"trials":2141,"activeCount":8},[2142,2150],{"nctId":2143,"briefTitle":2144,"status":61,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":266,"conditions":2148,"interventions":2149},"NCT01149980","Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions",[38],"2003-11","2003-10",[13],[2136],{"nctId":2151,"briefTitle":2152,"status":61,"phases":2153,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":266,"conditions":2154,"interventions":2155},"NCT01149967","Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions",[38],[13],[2136],{"trials":2157,"activeCount":8},[],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[],{"trials":2163,"activeCount":8},[],{"intervention":2165,"totalTrials":32,"cells":2166},"Olanzapine OD Tablets 5 mg",{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2168,"activeCount":8},[],{"trials":2170,"activeCount":8},[2171,2177],{"nctId":2172,"briefTitle":2173,"status":61,"phases":2174,"primaryCompletion":1470,"completion":1481,"start":1470,"enrollment":1135,"conditions":2175,"interventions":2176},"NCT01503437","Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition",[38],[16],[2165],{"nctId":2178,"briefTitle":2179,"status":61,"phases":2180,"primaryCompletion":1481,"completion":1481,"start":1470,"enrollment":1385,"conditions":2181,"interventions":2182},"NCT01503450","Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition",[38],[19],[2165],{"trials":2184,"activeCount":8},[],{"trials":2186,"activeCount":8},[],{"trials":2188,"activeCount":8},[],{"trials":2190,"activeCount":8},[],{"intervention":2192,"totalTrials":32,"cells":2193},"Meloxicam",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2195,"activeCount":8},[],{"trials":2197,"activeCount":8},[2198,2206],{"nctId":2199,"briefTitle":2200,"status":61,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":1620,"conditions":2204,"interventions":2205},"NCT01161134","Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition",[38],"2004-11","2004-09",[13],[2192],{"nctId":2207,"briefTitle":2208,"status":61,"phases":2209,"primaryCompletion":2210,"completion":2210,"start":1932,"enrollment":1620,"conditions":2211,"interventions":2212},"NCT01161147","Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition",[38],"2004-12",[13],[2192],{"trials":2214,"activeCount":8},[],{"trials":2216,"activeCount":8},[],{"trials":2218,"activeCount":8},[],{"trials":2220,"activeCount":8},[],{"intervention":2222,"totalTrials":32,"cells":2223},"Simvastatin",{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2242,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2225,"activeCount":8},[],{"trials":2227,"activeCount":8},[2228,2235],{"nctId":2229,"briefTitle":2230,"status":61,"phases":2231,"primaryCompletion":1868,"completion":1868,"start":2232,"enrollment":1757,"conditions":2233,"interventions":2234},"NCT01167933","Bioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions",[38],"2005-01",[13],[2222],{"nctId":2236,"briefTitle":2237,"status":61,"phases":2238,"primaryCompletion":1868,"completion":1868,"start":2232,"enrollment":2239,"conditions":2240,"interventions":2241},"NCT01167894","Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition",[38],72,[13],[2222],{"trials":2243,"activeCount":8},[],{"trials":2245,"activeCount":8},[],{"trials":2247,"activeCount":8},[],{"trials":2249,"activeCount":8},[],{"intervention":2251,"totalTrials":32,"cells":2252},"Pantoprazole Sodium",{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2277},{"trials":2254,"activeCount":8},[],{"trials":2256,"activeCount":8},[2257,2264],{"nctId":2258,"briefTitle":2259,"status":61,"phases":2260,"primaryCompletion":2210,"completion":2210,"start":1932,"enrollment":2261,"conditions":2262,"interventions":2263},"NCT01283932","Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition",[38],52,[1811],[2251],{"nctId":2265,"briefTitle":2266,"status":61,"phases":2267,"primaryCompletion":2210,"completion":2210,"start":1932,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT01283919","Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition",[38],42,[16],[2251],{"trials":2272,"activeCount":8},[],{"trials":2274,"activeCount":8},[],{"trials":2276,"activeCount":8},[],{"trials":2278,"activeCount":8},[],{"intervention":2280,"totalTrials":32,"cells":2281},"Tizanidine",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2283,"activeCount":8},[],{"trials":2285,"activeCount":8},[2286,2293],{"nctId":2287,"briefTitle":2288,"status":61,"phases":2289,"primaryCompletion":1671,"completion":2290,"start":1671,"enrollment":2268,"conditions":2291,"interventions":2292},"NCT01146028","Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions",[38],"2001-11",[13],[2280],{"nctId":2294,"briefTitle":2295,"status":61,"phases":2296,"primaryCompletion":1671,"completion":2290,"start":1671,"enrollment":266,"conditions":2297,"interventions":2298},"NCT01065987","Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions",[38],[13],[2280],{"trials":2300,"activeCount":8},[],{"trials":2302,"activeCount":8},[],{"trials":2304,"activeCount":8},[],{"trials":2306,"activeCount":8},[],{"intervention":2308,"totalTrials":32,"cells":2309},"Fluconazole",{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2311,"activeCount":8},[],{"trials":2313,"activeCount":8},[2314,2322],{"nctId":2315,"briefTitle":2316,"status":61,"phases":2317,"primaryCompletion":1679,"completion":2318,"start":1679,"enrollment":2319,"conditions":2320,"interventions":2321},"NCT01511770","Bioavailability Study of Fluconazole Tablets 200 mg Under Fasting Conditions",[38],"2002-09",17,[13],[2308,2308],{"nctId":2323,"briefTitle":2324,"status":61,"phases":2325,"primaryCompletion":2326,"completion":2327,"start":2326,"enrollment":2328,"conditions":2329,"interventions":2330},"NCT01511757","Bioavailability Study of Fluconazole Tablets 200 mg Under Fed Conditions",[38],"2002-06","2002-07",15,[13],[2308,2308],{"trials":2332,"activeCount":8},[],{"trials":2334,"activeCount":8},[],{"trials":2336,"activeCount":8},[],{"trials":2338,"activeCount":8},[],{"intervention":2340,"totalTrials":32,"cells":2341},"Ibuprofen",{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2358,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2343,"activeCount":8},[],{"trials":2345,"activeCount":8},[2346,2352],{"nctId":2347,"briefTitle":2348,"status":61,"phases":2349,"primaryCompletion":1437,"completion":1437,"start":1437,"enrollment":950,"conditions":2350,"interventions":2351},"NCT01149941","Bioequivalence Study of Ibuprofen 200 mg Gel Capsules of Dr. Reddy's Laboratories Under Fasting Condition",[38],[13],[2340],{"nctId":2353,"briefTitle":2354,"status":61,"phases":2355,"primaryCompletion":1384,"completion":1384,"start":1384,"enrollment":950,"conditions":2356,"interventions":2357},"NCT01149954","Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules of Dr. Reddy's Laboratories Limited Under Fed Conditions",[38],[13],[2340],{"trials":2359,"activeCount":8},[],{"trials":2361,"activeCount":8},[],{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[],{"intervention":2367,"totalTrials":32,"cells":2368},"Ibuprofen and Diphenhydramine Citrate",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2370,"activeCount":8},[],{"trials":2372,"activeCount":8},[2373,2380],{"nctId":2374,"briefTitle":2375,"status":61,"phases":2376,"primaryCompletion":2377,"completion":2377,"start":2377,"enrollment":200,"conditions":2378,"interventions":2379},"NCT01053208","Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg\u002F38 mg Caplets Under Fasting Condition",[38],"2008-04",[13],[2367],{"nctId":2381,"briefTitle":2382,"status":61,"phases":2383,"primaryCompletion":2377,"completion":2377,"start":2377,"enrollment":200,"conditions":2384,"interventions":2385},"NCT01053338","Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg\u002F38 mg Caplets Under Fed Condition",[38],[13],[2367],{"trials":2387,"activeCount":8},[],{"trials":2389,"activeCount":8},[],{"trials":2391,"activeCount":8},[],{"trials":2393,"activeCount":8},[],{"intervention":2395,"totalTrials":32,"cells":2396},"Amlodipine Besylate\u002FBenazepril HCl",{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2398,"activeCount":8},[],{"trials":2400,"activeCount":8},[2401,2409],{"nctId":2402,"briefTitle":2403,"status":61,"phases":2404,"primaryCompletion":2405,"completion":2405,"start":1480,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT01505998","Bioequivalence Study of Amlodipine Besylate\u002FBenazepril HCl 10 mg\u002F40 mg Capsules of Dr. Reddy's Under Fed Conditions",[38],"2007-05",49,[19],[2395],{"nctId":2410,"briefTitle":2411,"status":61,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":1480,"enrollment":223,"conditions":2414,"interventions":2415},"NCT01506011","Bioequivalence Study of Amlodipine Besylate\u002FBenazepril HCl 10 mg\u002F40 mg Capsules of Dr. Reddy's Under Fasting Conditions",[38],"2007-04",[16],[2395],{"trials":2417,"activeCount":8},[],{"trials":2419,"activeCount":8},[],{"trials":2421,"activeCount":8},[],{"trials":2423,"activeCount":8},[],{"intervention":2425,"totalTrials":32,"cells":2426},"Valacyclovir Hydrochloride",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2443,"PHASE3":2445,"PHASE4":2447,"NA":2449},{"trials":2428,"activeCount":8},[],{"trials":2430,"activeCount":8},[2431,2437],{"nctId":2432,"briefTitle":2433,"status":61,"phases":2434,"primaryCompletion":1488,"completion":2405,"start":1488,"enrollment":1472,"conditions":2435,"interventions":2436},"NCT01136538","Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition",[38],[13],[2425],{"nctId":2438,"briefTitle":2439,"status":61,"phases":2440,"primaryCompletion":1480,"completion":2405,"start":1488,"enrollment":1596,"conditions":2441,"interventions":2442},"NCT01136525","Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting Conditions",[38],[13],[2425],{"trials":2444,"activeCount":8},[],{"trials":2446,"activeCount":8},[],{"trials":2448,"activeCount":8},[],{"trials":2450,"activeCount":8},[],{"intervention":2452,"totalTrials":32,"cells":2453},"Desloratadine and pseudoephedrine",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2477},{"trials":2455,"activeCount":8},[],{"trials":2457,"activeCount":8},[2458,2465],{"nctId":2459,"briefTitle":2460,"status":61,"phases":2461,"completion":2462,"start":1750,"enrollment":1472,"conditions":2463,"interventions":2464},"NCT01373138","Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions",[38],"2006-05",[13],[2452],{"nctId":2466,"briefTitle":2467,"status":61,"phases":2468,"completion":1750,"start":1750,"enrollment":1757,"conditions":2469,"interventions":2470},"NCT01506791","Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions",[38],[13],[2452],{"trials":2472,"activeCount":8},[],{"trials":2474,"activeCount":8},[],{"trials":2476,"activeCount":8},[],{"trials":2478,"activeCount":8},[],{"intervention":2480,"totalTrials":32,"cells":2481},"Anastrozole",{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2500,"PHASE3":2502,"PHASE4":2504,"NA":2506},{"trials":2483,"activeCount":8},[],{"trials":2485,"activeCount":8},[2486,2494],{"nctId":2487,"briefTitle":2488,"status":61,"phases":2489,"primaryCompletion":2490,"completion":2491,"start":2039,"enrollment":1430,"conditions":2492,"interventions":2493},"NCT01155960","Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions",[38],"2008-06","2008-07",[13],[2480],{"nctId":2495,"briefTitle":2496,"status":61,"phases":2497,"primaryCompletion":2490,"completion":2491,"start":2039,"enrollment":1430,"conditions":2498,"interventions":2499},"NCT01155947","Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions",[38],[13],[2480],{"trials":2501,"activeCount":8},[],{"trials":2503,"activeCount":8},[],{"trials":2505,"activeCount":8},[],{"trials":2507,"activeCount":8},[],{"intervention":2509,"totalTrials":32,"cells":2510},"Donepezil Hydrochloride",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2532,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2512,"activeCount":8},[],{"trials":2514,"activeCount":8},[2515,2525],{"nctId":2516,"briefTitle":2517,"status":61,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":1385,"conditions":2522,"interventions":2523},"NCT01504503","Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition",[38],"2009-11","2009-12","2009-10",[13],[2509,2524],"Aricept",{"nctId":2526,"briefTitle":2527,"status":61,"phases":2528,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2529,"conditions":2530,"interventions":2531},"NCT01504516","Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition",[38],25,[13],[2509,2524],{"trials":2533,"activeCount":8},[],{"trials":2535,"activeCount":8},[],{"trials":2537,"activeCount":8},[],{"trials":2539,"activeCount":8},[],{"intervention":2524,"totalTrials":32,"cells":2541},{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2543,"activeCount":8},[],{"trials":2545,"activeCount":8},[2546,2550],{"nctId":2516,"briefTitle":2517,"status":61,"phases":2547,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":1385,"conditions":2548,"interventions":2549},[38],[13],[2509,2524],{"nctId":2526,"briefTitle":2527,"status":61,"phases":2551,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2529,"conditions":2552,"interventions":2553},[38],[13],[2509,2524],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[],{"trials":2559,"activeCount":8},[],{"trials":2561,"activeCount":8},[],{"intervention":2563,"totalTrials":32,"cells":2564},"Ramipril",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2585,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2566,"activeCount":8},[],{"trials":2568,"activeCount":8},[2569,2578],{"nctId":2570,"briefTitle":2571,"status":61,"phases":2572,"primaryCompletion":2573,"completion":2574,"start":2573,"enrollment":1462,"conditions":2575,"interventions":2576},"NCT01164774","Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions",[38],"2005-10","2005-11",[13],[2563,2577],"Altace",{"nctId":2579,"briefTitle":2580,"status":61,"phases":2581,"primaryCompletion":2582,"completion":2573,"start":2582,"enrollment":1462,"conditions":2583,"interventions":2584},"NCT01164761","Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions",[38],"2005-09",[13],[2563,2577],{"trials":2586,"activeCount":8},[],{"trials":2588,"activeCount":8},[],{"trials":2590,"activeCount":8},[],{"trials":2592,"activeCount":8},[],{"intervention":2577,"totalTrials":32,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2596,"activeCount":8},[],{"trials":2598,"activeCount":8},[2599,2603],{"nctId":2570,"briefTitle":2571,"status":61,"phases":2600,"primaryCompletion":2573,"completion":2574,"start":2573,"enrollment":1462,"conditions":2601,"interventions":2602},[38],[13],[2563,2577],{"nctId":2579,"briefTitle":2580,"status":61,"phases":2604,"primaryCompletion":2582,"completion":2573,"start":2582,"enrollment":1462,"conditions":2605,"interventions":2606},[38],[13],[2563,2577],{"trials":2608,"activeCount":8},[],{"trials":2610,"activeCount":8},[],{"trials":2612,"activeCount":8},[],{"trials":2614,"activeCount":8},[],{"intervention":2616,"totalTrials":32,"cells":2617},"Fluoxetine Hydrochloride",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2634,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2619,"activeCount":8},[],{"trials":2621,"activeCount":8},[2622,2628],{"nctId":2623,"briefTitle":2624,"status":61,"phases":2625,"primaryCompletion":1627,"completion":1471,"start":1619,"enrollment":1462,"conditions":2626,"interventions":2627},"NCT01166100","Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition",[38],[13],[2616],{"nctId":2629,"briefTitle":2630,"status":61,"phases":2631,"primaryCompletion":1627,"completion":1469,"start":1619,"enrollment":1462,"conditions":2632,"interventions":2633},"NCT01166087","Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition",[38],[13],[2616],{"trials":2635,"activeCount":8},[],{"trials":2637,"activeCount":8},[],{"trials":2639,"activeCount":8},[],{"trials":2641,"activeCount":8},[],{"intervention":2643,"totalTrials":32,"cells":2644},"Naproxen Sodium & Pseudoephedrine HCl",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2646,"activeCount":8},[],{"trials":2648,"activeCount":8},[2649,2656],{"nctId":2650,"briefTitle":2651,"status":61,"phases":2652,"primaryCompletion":1898,"completion":2203,"start":2653,"enrollment":1385,"conditions":2654,"interventions":2655},"NCT01131767","Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions",[38],"2004-07",[13],[2643],{"nctId":2657,"briefTitle":2658,"status":61,"phases":2659,"primaryCompletion":1898,"completion":2203,"start":2653,"enrollment":1385,"conditions":2660,"interventions":2661},"NCT01131728","Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fasting Conditions",[38],[13],[2643],{"trials":2663,"activeCount":8},[],{"trials":2665,"activeCount":8},[],{"trials":2667,"activeCount":8},[],{"trials":2669,"activeCount":8},[],{"intervention":2671,"totalTrials":32,"cells":2672},"Naproxen Sodium",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2674,"activeCount":8},[],{"trials":2676,"activeCount":8},[2677,2684],{"nctId":2678,"briefTitle":2679,"status":61,"phases":2680,"primaryCompletion":2462,"completion":2681,"start":2462,"enrollment":1385,"conditions":2682,"interventions":2683},"NCT01052792","Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions",[38],"2006-06",[13],[2671],{"nctId":2685,"briefTitle":2686,"status":61,"phases":2687,"primaryCompletion":2462,"completion":2462,"start":2462,"enrollment":1385,"conditions":2688,"interventions":2689},"NCT01052129","Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition",[38],[13],[2690],"Naproxen sodium",{"trials":2692,"activeCount":8},[],{"trials":2694,"activeCount":8},[],{"trials":2696,"activeCount":8},[],{"trials":2698,"activeCount":8},[],{"intervention":2700,"totalTrials":32,"cells":2701},"Trandolapril",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2703,"activeCount":8},[],{"trials":2705,"activeCount":8},[2706,2713],{"nctId":2707,"briefTitle":2708,"status":61,"phases":2709,"primaryCompletion":1750,"completion":2462,"start":1627,"enrollment":2261,"conditions":2710,"interventions":2711},"NCT01164800","Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions",[38],[13],[2700,2712],"Mavik",{"nctId":2714,"briefTitle":2715,"status":61,"phases":2716,"primaryCompletion":1750,"completion":2462,"start":1627,"enrollment":2261,"conditions":2717,"interventions":2718},"NCT01164787","Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions",[38],[13],[2700,2712],{"trials":2720,"activeCount":8},[],{"trials":2722,"activeCount":8},[],{"trials":2724,"activeCount":8},[],{"trials":2726,"activeCount":8},[],{"intervention":2712,"totalTrials":32,"cells":2728},{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2741,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2730,"activeCount":8},[],{"trials":2732,"activeCount":8},[2733,2737],{"nctId":2707,"briefTitle":2708,"status":61,"phases":2734,"primaryCompletion":1750,"completion":2462,"start":1627,"enrollment":2261,"conditions":2735,"interventions":2736},[38],[13],[2700,2712],{"nctId":2714,"briefTitle":2715,"status":61,"phases":2738,"primaryCompletion":1750,"completion":2462,"start":1627,"enrollment":2261,"conditions":2739,"interventions":2740},[38],[13],[2700,2712],{"trials":2742,"activeCount":8},[],{"trials":2744,"activeCount":8},[],{"trials":2746,"activeCount":8},[],{"trials":2748,"activeCount":8},[],{"intervention":2750,"totalTrials":32,"cells":2751},"Terbinafine Hydrochloride Tablets, 250 mg",{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2772,"PHASE3":2774,"PHASE4":2776,"NA":2778},{"trials":2753,"activeCount":8},[],{"trials":2755,"activeCount":8},[2756,2766],{"nctId":2757,"briefTitle":2758,"status":61,"phases":2759,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":2763,"conditions":2764,"interventions":2765},"NCT01286701","Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions",[38],"2002-02","2002-03","2002-01",18,[13],[2750],{"nctId":2767,"briefTitle":2768,"status":61,"phases":2769,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":1430,"conditions":2770,"interventions":2771},"NCT01286688","Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions",[38],[16],[2750],{"trials":2773,"activeCount":8},[],{"trials":2775,"activeCount":8},[],{"trials":2777,"activeCount":8},[],{"trials":2779,"activeCount":8},[],{"intervention":2781,"totalTrials":32,"cells":2782},"Donepezil",{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2784,"activeCount":8},[],{"trials":2786,"activeCount":8},[2787,2794],{"nctId":2788,"briefTitle":2789,"status":61,"phases":2790,"primaryCompletion":1393,"completion":2791,"start":1393,"enrollment":2040,"conditions":2792,"interventions":2793},"NCT01923558","Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition",[38],"2010-11",[13],[2781],{"nctId":2795,"briefTitle":2796,"status":61,"phases":2797,"primaryCompletion":1393,"completion":1960,"start":1393,"enrollment":2798,"conditions":2799,"interventions":2800},"NCT01923259","Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition",[38],94,[13],[2781],{"trials":2802,"activeCount":8},[],{"trials":2804,"activeCount":8},[],{"trials":2806,"activeCount":8},[],{"trials":2808,"activeCount":8},[],{"intervention":2810,"totalTrials":32,"cells":2811},"Sertraline",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2813,"activeCount":8},[],{"trials":2815,"activeCount":8},[2816,2822],{"nctId":2817,"briefTitle":2818,"status":61,"phases":2819,"primaryCompletion":1469,"completion":1528,"start":1469,"enrollment":1402,"conditions":2820,"interventions":2821},"NCT01267383","Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions",[38],[13],[2810],{"nctId":2823,"briefTitle":2824,"status":61,"phases":2825,"primaryCompletion":1469,"completion":1528,"start":1469,"enrollment":1402,"conditions":2826,"interventions":2827},"NCT01267396","Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions",[38],[13],[2810],{"trials":2829,"activeCount":8},[],{"trials":2831,"activeCount":8},[],{"trials":2833,"activeCount":8},[],{"trials":2835,"activeCount":8},[],{"intervention":2837,"totalTrials":32,"cells":2838},"Atorvastatin Calcium Tablets, 80 mg",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2859,"PHASE3":2861,"PHASE4":2863,"NA":2865},{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[2843,2852],{"nctId":2844,"briefTitle":2845,"status":61,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":2849,"conditions":2850,"interventions":2851},"NCT01645423","Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions",[38],"2009-09","2009-08",77,[13],[2837],{"nctId":2853,"briefTitle":2854,"status":61,"phases":2855,"primaryCompletion":1401,"completion":1401,"start":2856,"enrollment":2849,"conditions":2857,"interventions":2858},"NCT01645449","Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions",[38],"2010-06",[13],[2837],{"trials":2860,"activeCount":8},[],{"trials":2862,"activeCount":8},[],{"trials":2864,"activeCount":8},[],{"trials":2866,"activeCount":8},[],{"intervention":2868,"totalTrials":32,"cells":2869},"Nabumetone",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2871,"activeCount":8},[],{"trials":2873,"activeCount":8},[2874,2881],{"nctId":2875,"briefTitle":2876,"status":61,"phases":2877,"primaryCompletion":1627,"completion":1627,"start":1627,"enrollment":950,"conditions":2878,"interventions":2879},"NCT01164826","Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions",[38],[13],[2868,2880],"Relafen",{"nctId":2882,"briefTitle":2883,"status":61,"phases":2884,"primaryCompletion":1627,"completion":1627,"start":1627,"enrollment":1757,"conditions":2885,"interventions":2886},"NCT01164813","Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions",[38],[13],[2868,2880],{"trials":2888,"activeCount":8},[],{"trials":2890,"activeCount":8},[],{"trials":2892,"activeCount":8},[],{"trials":2894,"activeCount":8},[],{"intervention":2880,"totalTrials":32,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2909,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2898,"activeCount":8},[],{"trials":2900,"activeCount":8},[2901,2905],{"nctId":2875,"briefTitle":2876,"status":61,"phases":2902,"primaryCompletion":1627,"completion":1627,"start":1627,"enrollment":950,"conditions":2903,"interventions":2904},[38],[13],[2868,2880],{"nctId":2882,"briefTitle":2883,"status":61,"phases":2906,"primaryCompletion":1627,"completion":1627,"start":1627,"enrollment":1757,"conditions":2907,"interventions":2908},[38],[13],[2868,2880],{"trials":2910,"activeCount":8},[],{"trials":2912,"activeCount":8},[],{"trials":2914,"activeCount":8},[],{"trials":2916,"activeCount":8},[],{"intervention":2918,"totalTrials":32,"cells":2919},"Nizatidine",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2937,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2921,"activeCount":8},[],{"trials":2923,"activeCount":8},[2924,2931],{"nctId":2925,"briefTitle":2926,"status":61,"phases":2927,"primaryCompletion":2203,"completion":2203,"start":2653,"enrollment":1385,"conditions":2928,"interventions":2929},"NCT01161927","Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions",[38],[13],[2918,2930],"Axid",{"nctId":2932,"briefTitle":2933,"status":61,"phases":2934,"primaryCompletion":2203,"completion":2203,"start":2653,"enrollment":1385,"conditions":2935,"interventions":2936},"NCT01161940","Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions",[38],[13],[2918,2930],{"trials":2938,"activeCount":8},[],{"trials":2940,"activeCount":8},[],{"trials":2942,"activeCount":8},[],{"trials":2944,"activeCount":8},[],{"intervention":2930,"totalTrials":32,"cells":2946},{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2959,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2948,"activeCount":8},[],{"trials":2950,"activeCount":8},[2951,2955],{"nctId":2925,"briefTitle":2926,"status":61,"phases":2952,"primaryCompletion":2203,"completion":2203,"start":2653,"enrollment":1385,"conditions":2953,"interventions":2954},[38],[13],[2918,2930],{"nctId":2932,"briefTitle":2933,"status":61,"phases":2956,"primaryCompletion":2203,"completion":2203,"start":2653,"enrollment":1385,"conditions":2957,"interventions":2958},[38],[13],[2918,2930],{"trials":2960,"activeCount":8},[],{"trials":2962,"activeCount":8},[],{"trials":2964,"activeCount":8},[],{"trials":2966,"activeCount":8},[],{"intervention":2968,"totalTrials":32,"cells":2969},"Cetirizine Hydrochloride",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2986,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2971,"activeCount":8},[],{"trials":2973,"activeCount":8},[2974,2980],{"nctId":2975,"briefTitle":2976,"status":61,"phases":2977,"primaryCompletion":1634,"completion":1619,"start":1634,"enrollment":950,"conditions":2978,"interventions":2979},"NCT01064115","Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition",[38],[13],[2968],{"nctId":2981,"briefTitle":2982,"status":61,"phases":2983,"primaryCompletion":1634,"completion":1619,"start":1634,"enrollment":950,"conditions":2984,"interventions":2985},"NCT01064102","Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition",[38],[13],[2968],{"trials":2987,"activeCount":8},[],{"trials":2989,"activeCount":8},[],{"trials":2991,"activeCount":8},[],{"trials":2993,"activeCount":8},[],{"intervention":2995,"totalTrials":32,"cells":2996},"Valganciclovir Hydrochloride",{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":2998,"activeCount":8},[],{"trials":3000,"activeCount":8},[3001,3008],{"nctId":3002,"briefTitle":3003,"status":61,"phases":3004,"primaryCompletion":1270,"completion":657,"start":1270,"enrollment":3005,"conditions":3006,"interventions":3007},"NCT02297854","Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition",[38],83,[13],[2995],{"nctId":3009,"briefTitle":3010,"status":61,"phases":3011,"primaryCompletion":1270,"completion":657,"start":1270,"enrollment":3012,"conditions":3013,"interventions":3014},"NCT02296723","Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition",[38],66,[13],[2995],{"trials":3016,"activeCount":8},[],{"trials":3018,"activeCount":8},[],{"trials":3020,"activeCount":8},[],{"trials":3022,"activeCount":8},[],{"intervention":3024,"totalTrials":32,"cells":3025},"Ondansetron Hydrochloride",{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3042,"PHASE3":3044,"PHASE4":3046,"NA":3048},{"trials":3027,"activeCount":8},[],{"trials":3029,"activeCount":8},[3030,3036],{"nctId":3031,"briefTitle":3032,"status":61,"phases":3033,"primaryCompletion":1528,"completion":1528,"start":1528,"enrollment":1385,"conditions":3034,"interventions":3035},"NCT01511718","Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition",[38],[13],[3024,3024],{"nctId":3037,"briefTitle":3038,"status":61,"phases":3039,"primaryCompletion":1528,"completion":1528,"start":1528,"enrollment":1385,"conditions":3040,"interventions":3041},"NCT01511705","Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition",[38],[13],[3024,3024],{"trials":3043,"activeCount":8},[],{"trials":3045,"activeCount":8},[],{"trials":3047,"activeCount":8},[],{"trials":3049,"activeCount":8},[],{"intervention":3051,"totalTrials":32,"cells":3052},"Levetiracetam",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3054,"activeCount":8},[],{"trials":3056,"activeCount":8},[3057,3064],{"nctId":3058,"briefTitle":3059,"status":61,"phases":3060,"primaryCompletion":3061,"completion":2146,"start":3061,"enrollment":266,"conditions":3062,"interventions":3063},"NCT01131897","Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.",[38],"2003-09",[13],[3051],{"nctId":3065,"briefTitle":3066,"status":61,"phases":3067,"primaryCompletion":2147,"completion":2146,"start":3061,"enrollment":266,"conditions":3068,"interventions":3069},"NCT01132352","Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions",[38],[13],[3051],{"trials":3071,"activeCount":8},[],{"trials":3073,"activeCount":8},[],{"trials":3075,"activeCount":8},[],{"trials":3077,"activeCount":8},[],{"intervention":3079,"totalTrials":32,"cells":3080},"Reminyl",{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3097,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3082,"activeCount":8},[],{"trials":3084,"activeCount":8},[3085,3091],{"nctId":3086,"briefTitle":3087,"status":61,"phases":3088,"primaryCompletion":1932,"completion":2202,"start":1932,"enrollment":1620,"conditions":3089,"interventions":3090},"NCT01372280","Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition",[38],[16],[3079],{"nctId":3092,"briefTitle":3093,"status":61,"phases":3094,"primaryCompletion":2202,"completion":2202,"start":1932,"enrollment":266,"conditions":3095,"interventions":3096},"NCT01372306","Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition",[38],[19],[3079],{"trials":3098,"activeCount":8},[],{"trials":3100,"activeCount":8},[],{"trials":3102,"activeCount":8},[],{"trials":3104,"activeCount":8},[],{"intervention":3106,"totalTrials":32,"cells":3107},"Fexofenadine HCl + Pseudoephedrine HCl",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3124,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3109,"activeCount":8},[],{"trials":3111,"activeCount":8},[3112,3118],{"nctId":3113,"briefTitle":3114,"status":61,"phases":3115,"primaryCompletion":1488,"completion":2413,"start":1488,"enrollment":1462,"conditions":3116,"interventions":3117},"NCT01133470","Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions",[38],[13],[3106],{"nctId":3119,"briefTitle":3120,"status":61,"phases":3121,"primaryCompletion":2413,"completion":2405,"start":2413,"enrollment":1246,"conditions":3122,"interventions":3123},"NCT01133483","Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions",[38],[13],[3106],{"trials":3125,"activeCount":8},[],{"trials":3127,"activeCount":8},[],{"trials":3129,"activeCount":8},[],{"trials":3131,"activeCount":8},[],{"intervention":3133,"totalTrials":32,"cells":3134},"Rivastigmine",{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3153,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3136,"activeCount":8},[],{"trials":3138,"activeCount":8},[3139,3147],{"nctId":3140,"briefTitle":3141,"status":61,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":1757,"conditions":3145,"interventions":3146},"NCT01146067","Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions",[38],"2004-02","2004-01",[13],[3133],{"nctId":3148,"briefTitle":3149,"status":61,"phases":3150,"primaryCompletion":3143,"completion":1876,"start":3143,"enrollment":1757,"conditions":3151,"interventions":3152},"NCT01146041","Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions",[38],[13],[3133],{"trials":3154,"activeCount":8},[],{"trials":3156,"activeCount":8},[],{"trials":3158,"activeCount":8},[],{"trials":3160,"activeCount":8},[],{"intervention":3162,"totalTrials":32,"cells":3163},"Letrozole",{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3165,"activeCount":8},[],{"trials":3167,"activeCount":8},[3168,3174],{"nctId":3169,"briefTitle":3170,"status":61,"phases":3171,"primaryCompletion":2490,"completion":2490,"start":2377,"enrollment":1430,"conditions":3172,"interventions":3173},"NCT01372982","Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions",[38],[13],[3162],{"nctId":3175,"briefTitle":3176,"status":61,"phases":3177,"primaryCompletion":2039,"completion":2039,"start":1983,"enrollment":1430,"conditions":3178,"interventions":3179},"NCT01375452","Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions",[38],[13],[3162],{"trials":3181,"activeCount":8},[],{"trials":3183,"activeCount":8},[],{"trials":3185,"activeCount":8},[],{"trials":3187,"activeCount":8},[],{"intervention":3189,"totalTrials":32,"cells":3190},"Ropinirole",{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3192,"activeCount":8},[],{"trials":3194,"activeCount":8},[3195,3201],{"nctId":3196,"briefTitle":3197,"status":61,"phases":3198,"primaryCompletion":2521,"completion":2519,"start":2521,"enrollment":1802,"conditions":3199,"interventions":3200},"NCT01627847","Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition",[38],[13],[3189],{"nctId":3202,"briefTitle":3203,"status":61,"phases":3204,"primaryCompletion":2521,"completion":2519,"start":2521,"enrollment":1802,"conditions":3205,"interventions":3206},"NCT01627834","Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition",[38],[13],[3189],{"trials":3208,"activeCount":8},[],{"trials":3210,"activeCount":8},[],{"trials":3212,"activeCount":8},[],{"trials":3214,"activeCount":8},[],{"intervention":3216,"totalTrials":32,"cells":3217},"Tetrabenazine Tablets 25 mg",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3237,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3219,"activeCount":8},[],{"trials":3221,"activeCount":8},[3222,3229],{"nctId":3223,"briefTitle":3224,"status":61,"phases":3225,"primaryCompletion":3226,"completion":3226,"start":3226,"enrollment":1802,"conditions":3227,"interventions":3228},"NCT03702855","Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions",[38],"2015-12",[13],[3216],{"nctId":3230,"briefTitle":3231,"status":61,"phases":3232,"primaryCompletion":3233,"completion":3233,"start":3234,"enrollment":1802,"conditions":3235,"interventions":3236},"NCT03696329","Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions",[38],"2015-11","2015-10",[13],[3216],{"trials":3238,"activeCount":8},[],{"trials":3240,"activeCount":8},[],{"trials":3242,"activeCount":8},[],{"trials":3244,"activeCount":8},[],{"intervention":3246,"totalTrials":32,"cells":3247},"Metformin",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3266,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3249,"activeCount":8},[],{"trials":3251,"activeCount":8},[3252,3259],{"nctId":3253,"briefTitle":3254,"status":61,"phases":3255,"primaryCompletion":1868,"completion":1868,"start":2232,"enrollment":1462,"conditions":3256,"interventions":3257},"NCT01160042","Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition",[38],[13],[3246,3258],"Glucophage",{"nctId":3260,"briefTitle":3261,"status":61,"phases":3262,"primaryCompletion":1867,"completion":1867,"start":3263,"enrollment":223,"conditions":3264,"interventions":3265},"NCT01160068","Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition",[38],"2005-02",[13],[3246,3258],{"trials":3267,"activeCount":8},[],{"trials":3269,"activeCount":8},[],{"trials":3271,"activeCount":8},[],{"trials":3273,"activeCount":8},[],{"intervention":3258,"totalTrials":32,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3288,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3277,"activeCount":8},[],{"trials":3279,"activeCount":8},[3280,3284],{"nctId":3253,"briefTitle":3254,"status":61,"phases":3281,"primaryCompletion":1868,"completion":1868,"start":2232,"enrollment":1462,"conditions":3282,"interventions":3283},[38],[13],[3246,3258],{"nctId":3260,"briefTitle":3261,"status":61,"phases":3285,"primaryCompletion":1867,"completion":1867,"start":3263,"enrollment":223,"conditions":3286,"interventions":3287},[38],[13],[3246,3258],{"trials":3289,"activeCount":8},[],{"trials":3291,"activeCount":8},[],{"trials":3293,"activeCount":8},[],{"trials":3295,"activeCount":8},[],{"intervention":3297,"totalTrials":32,"cells":3298},"Olanzapine",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3300,"activeCount":8},[],{"trials":3302,"activeCount":8},[3303,3310],{"nctId":3304,"briefTitle":3305,"status":61,"phases":3306,"primaryCompletion":3307,"completion":3307,"start":657,"enrollment":1802,"conditions":3308,"interventions":3309},"NCT01503424","Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study",[38],"2011-09",[19],[3297],{"nctId":3311,"briefTitle":3312,"status":61,"phases":3313,"primaryCompletion":3307,"completion":3307,"start":657,"enrollment":1802,"conditions":3314,"interventions":3315},"NCT01503398","Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions",[38],[16],[3297],{"trials":3317,"activeCount":8},[],{"trials":3319,"activeCount":8},[],{"trials":3321,"activeCount":8},[],{"trials":3323,"activeCount":8},[],{"intervention":3325,"totalTrials":32,"cells":3326},"Ibuprofen + Pseudoephedrine Hydrochloride",{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3343,"PHASE3":3345,"PHASE4":3347,"NA":3349},{"trials":3328,"activeCount":8},[],{"trials":3330,"activeCount":8},[3331,3337],{"nctId":3332,"briefTitle":3333,"status":61,"phases":3334,"primaryCompletion":1932,"completion":2202,"start":1932,"enrollment":1402,"conditions":3335,"interventions":3336},"NCT01131780","Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions",[38],[13],[3325],{"nctId":3338,"briefTitle":3339,"status":61,"phases":3340,"primaryCompletion":1932,"completion":1932,"start":2203,"enrollment":1472,"conditions":3341,"interventions":3342},"NCT01132222","Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions",[38],[13],[3325],{"trials":3344,"activeCount":8},[],{"trials":3346,"activeCount":8},[],{"trials":3348,"activeCount":8},[],{"trials":3350,"activeCount":8},[],{"intervention":3352,"totalTrials":32,"cells":3353},"Zonisamide",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3372,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3355,"activeCount":8},[],{"trials":3357,"activeCount":8},[3358,3366],{"nctId":3359,"briefTitle":3360,"status":61,"phases":3361,"primaryCompletion":3263,"completion":3362,"start":2232,"enrollment":1385,"conditions":3363,"interventions":3364},"NCT01161979","Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions",[38],"2005-03",[13],[3352,3365],"Zonegran",{"nctId":3367,"briefTitle":3368,"status":61,"phases":3369,"primaryCompletion":3263,"completion":3362,"start":2232,"enrollment":1385,"conditions":3370,"interventions":3371},"NCT01161966","Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions",[38],[13],[3352,3365],{"trials":3373,"activeCount":8},[],{"trials":3375,"activeCount":8},[],{"trials":3377,"activeCount":8},[],{"trials":3379,"activeCount":8},[],{"intervention":3365,"totalTrials":32,"cells":3381},{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3394,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3383,"activeCount":8},[],{"trials":3385,"activeCount":8},[3386,3390],{"nctId":3359,"briefTitle":3360,"status":61,"phases":3387,"primaryCompletion":3263,"completion":3362,"start":2232,"enrollment":1385,"conditions":3388,"interventions":3389},[38],[13],[3352,3365],{"nctId":3367,"briefTitle":3368,"status":61,"phases":3391,"primaryCompletion":3263,"completion":3362,"start":2232,"enrollment":1385,"conditions":3392,"interventions":3393},[38],[13],[3352,3365],{"trials":3395,"activeCount":8},[],{"trials":3397,"activeCount":8},[],{"trials":3399,"activeCount":8},[],{"trials":3401,"activeCount":8},[],{"intervention":3403,"totalTrials":32,"cells":3404},"Sirolimus",{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3422,"PHASE3":3424,"PHASE4":3426,"NA":3428},{"trials":3406,"activeCount":8},[],{"trials":3408,"activeCount":8},[3409,3415],{"nctId":3410,"briefTitle":3411,"status":61,"phases":3412,"primaryCompletion":1574,"completion":1574,"start":1574,"enrollment":1430,"conditions":3413,"interventions":3414},"NCT02296762","Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition",[38],[13],[3403],{"nctId":3416,"briefTitle":3417,"status":61,"phases":3418,"primaryCompletion":3419,"completion":1574,"start":3419,"enrollment":825,"conditions":3420,"interventions":3421},"NCT02296749","Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition",[38],"2010-01",[13],[3403],{"trials":3423,"activeCount":8},[],{"trials":3425,"activeCount":8},[],{"trials":3427,"activeCount":8},[],{"trials":3429,"activeCount":8},[],{"intervention":3431,"totalTrials":32,"cells":3432},"Amlodipine besylate\u002FAtorvastatin calcium",{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3434,"activeCount":8},[],{"trials":3436,"activeCount":8},[3437,3445],{"nctId":3438,"briefTitle":3439,"status":61,"phases":3440,"primaryCompletion":3307,"completion":3441,"start":3307,"enrollment":3442,"conditions":3443,"interventions":3444},"NCT02292069","Bioavailability Study of Amlodipine Besylate\u002FAtorvastatin Calcium Tablets 10\u002F80 mg Under Fed Condition",[38],"2011-10",90,[13],[3431],{"nctId":3446,"briefTitle":3447,"status":61,"phases":3448,"primaryCompletion":3441,"completion":3449,"start":3441,"enrollment":3450,"conditions":3451,"interventions":3452},"NCT02295046","Bioavailability Study of Amlodipine Besylate\u002FAtorvastatin Calcium Tablets 10\u002F80 mg Under Fasting Condition",[38],"2011-11",80,[13],[3431],{"trials":3454,"activeCount":8},[],{"trials":3456,"activeCount":8},[],{"trials":3458,"activeCount":8},[],{"trials":3460,"activeCount":8},[],{"intervention":3462,"totalTrials":32,"cells":3463},"CIPRO®XR",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3480,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3465,"activeCount":8},[],{"trials":3467,"activeCount":8},[3468,3474],{"nctId":3469,"briefTitle":3470,"status":61,"phases":3471,"primaryCompletion":2232,"completion":3263,"start":2232,"enrollment":1402,"conditions":3472,"interventions":3473},"NCT01372358","Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions",[38],[19],[3462],{"nctId":3475,"briefTitle":3476,"status":61,"phases":3477,"primaryCompletion":3263,"completion":3362,"start":3263,"enrollment":1575,"conditions":3478,"interventions":3479},"NCT01372345","Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions",[38],[16],[3462],{"trials":3481,"activeCount":8},[],{"trials":3483,"activeCount":8},[],{"trials":3485,"activeCount":8},[],{"trials":3487,"activeCount":8},[],{"intervention":3489,"totalTrials":32,"cells":3490},"Amlodipine",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3508,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3492,"activeCount":8},[],{"trials":3494,"activeCount":8},[3495,3502],{"nctId":3496,"briefTitle":3497,"status":61,"phases":3498,"primaryCompletion":1437,"completion":1421,"start":3499,"enrollment":1385,"conditions":3500,"interventions":3501},"NCT01131923","Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions",[38],"2002-10",[13],[3489],{"nctId":3503,"briefTitle":3504,"status":61,"phases":3505,"primaryCompletion":2318,"completion":1437,"start":1679,"enrollment":266,"conditions":3506,"interventions":3507},"NCT01131936","Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fed Conditions",[38],[13],[3489],{"trials":3509,"activeCount":8},[],{"trials":3511,"activeCount":8},[],{"trials":3513,"activeCount":8},[],{"trials":3515,"activeCount":8},[],{"intervention":1425,"totalTrials":32,"cells":3517},{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3530,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3519,"activeCount":8},[],{"trials":3521,"activeCount":8},[3522,3526],{"nctId":1418,"briefTitle":1419,"status":61,"phases":3523,"primaryCompletion":1421,"completion":1421,"start":1421,"enrollment":1422,"conditions":3524,"interventions":3525},[38],[13],[1371,1425],{"nctId":1434,"briefTitle":1435,"status":61,"phases":3527,"primaryCompletion":1437,"completion":1437,"start":1437,"enrollment":1422,"conditions":3528,"interventions":3529},[38],[13],[1371,1425],{"trials":3531,"activeCount":8},[],{"trials":3533,"activeCount":8},[],{"trials":3535,"activeCount":8},[],{"trials":3537,"activeCount":8},[],{"intervention":3539,"totalTrials":32,"cells":3540},"Fexofenadine",{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3557,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3542,"activeCount":8},[],{"trials":3544,"activeCount":8},[3545,3551],{"nctId":3546,"briefTitle":3547,"status":61,"phases":3548,"primaryCompletion":1716,"completion":1716,"start":1715,"enrollment":1757,"conditions":3549,"interventions":3550},"NCT01066754","Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions",[38],[13],[3539],{"nctId":3552,"briefTitle":3553,"status":61,"phases":3554,"primaryCompletion":1716,"completion":1716,"start":1715,"enrollment":950,"conditions":3555,"interventions":3556},"NCT01066767","Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions",[38],[13],[3539],{"trials":3558,"activeCount":8},[],{"trials":3560,"activeCount":8},[],{"trials":3562,"activeCount":8},[],{"trials":3564,"activeCount":8},[],{"intervention":3566,"totalTrials":32,"cells":3567},"Pravastatin Sodium",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3569,"activeCount":8},[],{"trials":3571,"activeCount":8},[3572,3578],{"nctId":3573,"briefTitle":3574,"status":61,"phases":3575,"primaryCompletion":1437,"completion":1383,"start":1437,"enrollment":266,"conditions":3576,"interventions":3577},"NCT01146093","Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions",[38],[13],[3566],{"nctId":3579,"briefTitle":3580,"status":61,"phases":3581,"primaryCompletion":1421,"completion":1421,"start":1421,"enrollment":1575,"conditions":3582,"interventions":3583},"NCT01146106","Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions",[38],[13],[3566],{"trials":3585,"activeCount":8},[],{"trials":3587,"activeCount":8},[],{"trials":3589,"activeCount":8},[],{"trials":3591,"activeCount":8},[],{"intervention":3593,"totalTrials":32,"cells":3594},"Ziprasidone Hydrochloride",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3596,"activeCount":8},[],{"trials":3598,"activeCount":8},[3599,3605],{"nctId":3600,"briefTitle":3601,"status":61,"phases":3602,"primaryCompletion":2202,"completion":2232,"start":2202,"enrollment":1246,"conditions":3603,"interventions":3604},"NCT01581879","Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions",[38],[13],[3593],{"nctId":3606,"briefTitle":3607,"status":61,"phases":3608,"primaryCompletion":2202,"completion":2232,"start":2202,"enrollment":3609,"conditions":3610,"interventions":3611},"NCT01581866","Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions",[38],56,[13],[3593],{"trials":3613,"activeCount":8},[],{"trials":3615,"activeCount":8},[],{"trials":3617,"activeCount":8},[],{"trials":3619,"activeCount":8},[],{"intervention":3621,"totalTrials":32,"cells":3622},"Atorvastatin Calcium Tablets, 40 mg",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3646,"PHASE3":3648,"PHASE4":3650,"NA":3652},{"trials":3624,"activeCount":8},[],{"trials":3626,"activeCount":8},[3627,3637],{"nctId":3628,"briefTitle":3629,"status":61,"phases":3630,"primaryCompletion":3631,"completion":3632,"start":3633,"enrollment":3634,"conditions":3635,"interventions":3636},"NCT01645410","Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions",[38],"2009-04","2009-05","2009-03",71,[13],[3621],{"nctId":3638,"briefTitle":3639,"status":61,"phases":3640,"primaryCompletion":3641,"completion":3642,"start":3632,"enrollment":3643,"conditions":3644,"interventions":3645},"NCT01645384","Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions",[38],"2009-06","2009-07",69,[13],[3621],{"trials":3647,"activeCount":8},[],{"trials":3649,"activeCount":8},[],{"trials":3651,"activeCount":8},[],{"trials":3653,"activeCount":8},[],{"intervention":3655,"totalTrials":46,"cells":3656},"Ranitidine",{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3667,"PHASE3":3669,"PHASE4":3671,"NA":3673},{"trials":3658,"activeCount":8},[],{"trials":3660,"activeCount":8},[3661],{"nctId":3662,"briefTitle":3663,"status":61,"phases":3664,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":266,"conditions":3665,"interventions":3666},"NCT01131702","Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions",[38],[13],[3655],{"trials":3668,"activeCount":8},[],{"trials":3670,"activeCount":8},[],{"trials":3672,"activeCount":8},[],{"trials":3674,"activeCount":8},[],{"intervention":3676,"totalTrials":46,"cells":3677},"Montelukast sodium chewable tablets 4 mg and 5 mg",{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3688,"PHASE3":3690,"PHASE4":3692,"NA":3694},{"trials":3679,"activeCount":8},[],{"trials":3681,"activeCount":8},[3682],{"nctId":3683,"briefTitle":3684,"status":61,"phases":3685,"primaryCompletion":3419,"completion":3419,"start":3419,"enrollment":1341,"conditions":3686,"interventions":3687},"NCT01674504","Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fasting Condition",[38],[13],[3676],{"trials":3689,"activeCount":8},[],{"trials":3691,"activeCount":8},[],{"trials":3693,"activeCount":8},[],{"trials":3695,"activeCount":8},[],{"intervention":3697,"totalTrials":46,"cells":3698},"Test Product",{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3700,"activeCount":8},[],{"trials":3702,"activeCount":8},[3703],{"nctId":3704,"briefTitle":3705,"status":151,"phases":3706,"primaryCompletion":3707,"completion":3708,"start":3709,"enrollment":3710,"conditions":3711,"interventions":3712},"NCT06126042","Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route",[38],"2024-04","2024-07","2023-10-03",330,[28],[3697,3713,3714],"Reference product","Reference Medicinal Product",{"trials":3716,"activeCount":8},[],{"trials":3718,"activeCount":8},[],{"trials":3720,"activeCount":8},[],{"trials":3722,"activeCount":8},[],{"intervention":3713,"totalTrials":46,"cells":3724},{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3733,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3726,"activeCount":8},[],{"trials":3728,"activeCount":8},[3729],{"nctId":3704,"briefTitle":3705,"status":151,"phases":3730,"primaryCompletion":3707,"completion":3708,"start":3709,"enrollment":3710,"conditions":3731,"interventions":3732},[38],[28],[3697,3713,3714],{"trials":3734,"activeCount":8},[],{"trials":3736,"activeCount":8},[],{"trials":3738,"activeCount":8},[],{"trials":3740,"activeCount":8},[],{"intervention":3714,"totalTrials":46,"cells":3742},{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3751,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3744,"activeCount":8},[],{"trials":3746,"activeCount":8},[3747],{"nctId":3704,"briefTitle":3705,"status":151,"phases":3748,"primaryCompletion":3707,"completion":3708,"start":3709,"enrollment":3710,"conditions":3749,"interventions":3750},[38],[28],[3697,3713,3714],{"trials":3752,"activeCount":8},[],{"trials":3754,"activeCount":8},[],{"trials":3756,"activeCount":8},[],{"trials":3758,"activeCount":8},[],{"intervention":3760,"totalTrials":46,"cells":3761},"Quetiapine fumarate",{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3772,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3763,"activeCount":8},[],{"trials":3765,"activeCount":8},[3766],{"nctId":3767,"briefTitle":3768,"status":61,"phases":3769,"primaryCompletion":2856,"completion":2856,"start":2856,"enrollment":1462,"conditions":3770,"interventions":3771},"NCT01566487","Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition",[38],[13],[3760],{"trials":3773,"activeCount":8},[],{"trials":3775,"activeCount":8},[],{"trials":3777,"activeCount":8},[],{"trials":3779,"activeCount":8},[],{"intervention":3781,"totalTrials":46,"cells":3782},"Zafirlukast",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3784,"activeCount":8},[],{"trials":3786,"activeCount":8},[3787],{"nctId":3788,"briefTitle":3789,"status":61,"phases":3790,"primaryCompletion":1984,"completion":1984,"start":1800,"enrollment":1757,"conditions":3791,"interventions":3792},"NCT01283061","Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition",[38],[13],[3781],{"trials":3794,"activeCount":8},[],{"trials":3796,"activeCount":8},[],{"trials":3798,"activeCount":8},[],{"trials":3800,"activeCount":8},[],{"intervention":3802,"totalTrials":46,"cells":3803},"Fexofenadine Hydrochloride",{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3814,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3805,"activeCount":8},[],{"trials":3807,"activeCount":8},[3808],{"nctId":3809,"briefTitle":3810,"status":61,"phases":3811,"primaryCompletion":1460,"completion":180,"start":1460,"enrollment":3450,"conditions":3812,"interventions":3813},"NCT01888718","Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition",[38],[13],[3802],{"trials":3815,"activeCount":8},[],{"trials":3817,"activeCount":8},[],{"trials":3819,"activeCount":8},[],{"trials":3821,"activeCount":8},[],{"intervention":3823,"totalTrials":46,"cells":3824},"DFN-15",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3839,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3826,"activeCount":8},[],{"trials":3828,"activeCount":8},[3829],{"nctId":3830,"briefTitle":3831,"status":61,"phases":3832,"primaryCompletion":3833,"completion":3834,"start":3835,"enrollment":266,"conditions":3836,"interventions":3837},"NCT03282838","Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects",[38],"2017-08-22","2018-01-12","2017-06-09",[1343],[3823,3823,3838],"Comparator Celebrex®",{"trials":3840,"activeCount":8},[],{"trials":3842,"activeCount":8},[],{"trials":3844,"activeCount":8},[],{"trials":3846,"activeCount":8},[],{"intervention":3838,"totalTrials":46,"cells":3848},{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3857,"PHASE3":3859,"PHASE4":3861,"NA":3863},{"trials":3850,"activeCount":8},[],{"trials":3852,"activeCount":8},[3853],{"nctId":3830,"briefTitle":3831,"status":61,"phases":3854,"primaryCompletion":3833,"completion":3834,"start":3835,"enrollment":266,"conditions":3855,"interventions":3856},[38],[1343],[3823,3823,3838],{"trials":3858,"activeCount":8},[],{"trials":3860,"activeCount":8},[],{"trials":3862,"activeCount":8},[],{"trials":3864,"activeCount":8},[],{"intervention":3866,"totalTrials":46,"cells":3867},"Glimepiride",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3869,"activeCount":8},[],{"trials":3871,"activeCount":8},[3872],{"nctId":3873,"briefTitle":3874,"status":61,"phases":3875,"primaryCompletion":3876,"completion":3876,"start":3876,"enrollment":1757,"conditions":3877,"interventions":3878},"NCT01052909","Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition",[38],"2003-12",[13],[3866],{"trials":3880,"activeCount":8},[],{"trials":3882,"activeCount":8},[],{"trials":3884,"activeCount":8},[],{"trials":3886,"activeCount":8},[],{"intervention":3888,"totalTrials":46,"cells":3889},"Montelukast sodium chewable tablets 4mg and 5mg",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3900,"PHASE3":3902,"PHASE4":3904,"NA":3906},{"trials":3891,"activeCount":8},[],{"trials":3893,"activeCount":8},[3894],{"nctId":3895,"briefTitle":3896,"status":61,"phases":3897,"primaryCompletion":1574,"completion":1574,"start":1574,"enrollment":1635,"conditions":3898,"interventions":3899},"NCT01674517","Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fed Condition",[38],[13],[3888],{"trials":3901,"activeCount":8},[],{"trials":3903,"activeCount":8},[],{"trials":3905,"activeCount":8},[],{"trials":3907,"activeCount":8},[],{"intervention":3909,"totalTrials":46,"cells":3910},"Paricalcitol Capsules, 4 mcg",{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3921,"PHASE3":3923,"PHASE4":3925,"NA":3927},{"trials":3912,"activeCount":8},[],{"trials":3914,"activeCount":8},[3915],{"nctId":3916,"briefTitle":3917,"status":61,"phases":3918,"primaryCompletion":1960,"completion":1460,"start":2791,"enrollment":3643,"conditions":3919,"interventions":3920},"NCT02322632","Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions",[38],[13],[3909],{"trials":3922,"activeCount":8},[],{"trials":3924,"activeCount":8},[],{"trials":3926,"activeCount":8},[],{"trials":3928,"activeCount":8},[],{"intervention":3930,"totalTrials":46,"cells":3931},"Famotidine",{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3944,"PHASE3":3946,"PHASE4":3948,"NA":3950},{"trials":3933,"activeCount":8},[],{"trials":3935,"activeCount":8},[3936],{"nctId":3937,"briefTitle":3938,"status":61,"phases":3939,"primaryCompletion":3940,"completion":3940,"start":3940,"enrollment":950,"conditions":3941,"interventions":3942},"NCT01511731","Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions",[38],"1998-10",[13],[3930,3943],"Pepcid",{"trials":3945,"activeCount":8},[],{"trials":3947,"activeCount":8},[],{"trials":3949,"activeCount":8},[],{"trials":3951,"activeCount":8},[],{"intervention":3943,"totalTrials":46,"cells":3953},{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3955,"activeCount":8},[],{"trials":3957,"activeCount":8},[3958],{"nctId":3937,"briefTitle":3938,"status":61,"phases":3959,"primaryCompletion":3940,"completion":3940,"start":3940,"enrollment":950,"conditions":3960,"interventions":3961},[38],[13],[3930,3943],{"trials":3963,"activeCount":8},[],{"trials":3965,"activeCount":8},[],{"trials":3967,"activeCount":8},[],{"trials":3969,"activeCount":8},[],{"intervention":204,"totalTrials":46,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3980,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":8},[],{"trials":3975,"activeCount":8},[3976],{"nctId":195,"briefTitle":196,"status":61,"phases":3977,"primaryCompletion":198,"completion":199,"start":198,"enrollment":200,"conditions":3978,"interventions":3979},[38],[202],[188,204,205],{"trials":3981,"activeCount":8},[],{"trials":3983,"activeCount":8},[],{"trials":3985,"activeCount":8},[],{"trials":3987,"activeCount":8},[],{"intervention":205,"totalTrials":46,"cells":3989},{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4004},{"trials":3991,"activeCount":8},[],{"trials":3993,"activeCount":8},[3994],{"nctId":195,"briefTitle":196,"status":61,"phases":3995,"primaryCompletion":198,"completion":199,"start":198,"enrollment":200,"conditions":3996,"interventions":3997},[38],[202],[188,204,205],{"trials":3999,"activeCount":8},[],{"trials":4001,"activeCount":8},[],{"trials":4003,"activeCount":8},[],{"trials":4005,"activeCount":8},[],{"intervention":1760,"totalTrials":46,"cells":4007},{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4016,"PHASE3":4018,"PHASE4":4020,"NA":4022},{"trials":4009,"activeCount":8},[],{"trials":4011,"activeCount":8},[4012],{"nctId":1754,"briefTitle":1755,"status":61,"phases":4013,"primaryCompletion":1627,"completion":1627,"start":1634,"enrollment":1757,"conditions":4014,"interventions":4015},[38],[13],[1740,1760],{"trials":4017,"activeCount":8},[],{"trials":4019,"activeCount":8},[],{"trials":4021,"activeCount":8},[],{"trials":4023,"activeCount":8},[],{"intervention":4025,"totalTrials":46,"cells":4026},"Alendronate Sodium Tablets, 70 mg",{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4037,"PHASE3":4039,"PHASE4":4041,"NA":4043},{"trials":4028,"activeCount":8},[],{"trials":4030,"activeCount":8},[4031],{"nctId":4032,"briefTitle":4033,"status":61,"phases":4034,"primaryCompletion":1481,"completion":2413,"start":1481,"enrollment":3450,"conditions":4035,"interventions":4036},"NCT01133496","Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions",[38],[13],[4025],{"trials":4038,"activeCount":8},[],{"trials":4040,"activeCount":8},[],{"trials":4042,"activeCount":8},[],{"trials":4044,"activeCount":8},[],{"intervention":4046,"totalTrials":46,"cells":4047},"Glimepiride tablets 1 mg",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4049,"activeCount":8},[],{"trials":4051,"activeCount":8},[4052],{"nctId":4053,"briefTitle":4054,"status":61,"phases":4055,"primaryCompletion":3876,"completion":3876,"start":3876,"enrollment":1757,"conditions":4056,"interventions":4057},"NCT01053689","Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed Condition",[38],[13],[4046],{"trials":4059,"activeCount":8},[],{"trials":4061,"activeCount":8},[],{"trials":4063,"activeCount":8},[],{"trials":4065,"activeCount":8},[],{"intervention":4067,"totalTrials":46,"cells":4068},"Moxifloxacin Tablets 400 mg",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4081,"PHASE3":4083,"PHASE4":4085,"NA":4087},{"trials":4070,"activeCount":8},[],{"trials":4072,"activeCount":8},[4073],{"nctId":4074,"briefTitle":4075,"status":61,"phases":4076,"primaryCompletion":4077,"completion":4077,"start":4078,"enrollment":1385,"conditions":4079,"interventions":4080},"NCT02322619","Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions",[38],"2012-12","2012-11",[13],[4067],{"trials":4082,"activeCount":8},[],{"trials":4084,"activeCount":8},[],{"trials":4086,"activeCount":8},[],{"trials":4088,"activeCount":8},[],{"intervention":4090,"totalTrials":46,"cells":4091},"Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200\u002F120 mg",{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4104,"PHASE3":4106,"PHASE4":4108,"NA":4110},{"trials":4093,"activeCount":8},[],{"trials":4095,"activeCount":8},[4096],{"nctId":4097,"briefTitle":4098,"status":61,"phases":4099,"primaryCompletion":4100,"completion":4100,"start":4101,"enrollment":3450,"conditions":4102,"interventions":4103},"NCT03706300","Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200\u002F120 mg Under Fasting Conditions",[38],"2015-01","2014-12",[13],[4090],{"trials":4105,"activeCount":8},[],{"trials":4107,"activeCount":8},[],{"trials":4109,"activeCount":8},[],{"trials":4111,"activeCount":8},[],{"intervention":4113,"totalTrials":46,"cells":4114},"Ibandronate sodium",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4126,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4116,"activeCount":8},[],{"trials":4118,"activeCount":8},[4119],{"nctId":4120,"briefTitle":4121,"status":61,"phases":4122,"primaryCompletion":1543,"completion":1838,"start":1543,"enrollment":4123,"conditions":4124,"interventions":4125},"NCT01627886","Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition",[38],100,[13],[4113],{"trials":4127,"activeCount":8},[],{"trials":4129,"activeCount":8},[],{"trials":4131,"activeCount":8},[],{"trials":4133,"activeCount":8},[],{"intervention":4135,"totalTrials":46,"cells":4136},"Venlafaxine",{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4138,"activeCount":8},[],{"trials":4140,"activeCount":8},[4141],{"nctId":4142,"briefTitle":4143,"status":61,"phases":4144,"primaryCompletion":2462,"completion":2681,"start":2462,"enrollment":4145,"conditions":4146,"interventions":4147},"NCT01512459","Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions",[38],33,[13],[4135],{"trials":4149,"activeCount":8},[],{"trials":4151,"activeCount":8},[],{"trials":4153,"activeCount":8},[],{"trials":4155,"activeCount":8},[],{"intervention":4157,"totalTrials":46,"cells":4158},"DRL_PG",{"EARLY_PHASE1":4159,"PHASE1":4161,"PHASE2":4173,"PHASE3":4175,"PHASE4":4177,"NA":4179},{"trials":4160,"activeCount":8},[],{"trials":4162,"activeCount":8},[4163],{"nctId":4164,"briefTitle":4165,"status":151,"phases":4166,"primaryCompletion":234,"completion":221,"start":235,"enrollment":4167,"conditions":4168,"interventions":4170},"NCT02205320","A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers",[38],192,[4169],"Pharmacokinetics",[4157,4171,4172],"Pegfilgrastim Form A","Pegfilgrastim Form B",{"trials":4174,"activeCount":8},[],{"trials":4176,"activeCount":8},[],{"trials":4178,"activeCount":8},[],{"trials":4180,"activeCount":8},[],{"intervention":4171,"totalTrials":46,"cells":4182},{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4191,"PHASE3":4193,"PHASE4":4195,"NA":4197},{"trials":4184,"activeCount":8},[],{"trials":4186,"activeCount":8},[4187],{"nctId":4164,"briefTitle":4165,"status":151,"phases":4188,"primaryCompletion":234,"completion":221,"start":235,"enrollment":4167,"conditions":4189,"interventions":4190},[38],[4169],[4157,4171,4172],{"trials":4192,"activeCount":8},[],{"trials":4194,"activeCount":8},[],{"trials":4196,"activeCount":8},[],{"trials":4198,"activeCount":8},[],{"intervention":4172,"totalTrials":46,"cells":4200},{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4209,"PHASE3":4211,"PHASE4":4213,"NA":4215},{"trials":4202,"activeCount":8},[],{"trials":4204,"activeCount":8},[4205],{"nctId":4164,"briefTitle":4165,"status":151,"phases":4206,"primaryCompletion":234,"completion":221,"start":235,"enrollment":4167,"conditions":4207,"interventions":4208},[38],[4169],[4157,4171,4172],{"trials":4210,"activeCount":8},[],{"trials":4212,"activeCount":8},[],{"trials":4214,"activeCount":8},[],{"trials":4216,"activeCount":8},[],{"intervention":4218,"totalTrials":46,"cells":4219},"Ha44",{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4235,"PHASE3":4237,"PHASE4":4239,"NA":4241},{"trials":4221,"activeCount":8},[],{"trials":4223,"activeCount":8},[4224],{"nctId":4225,"briefTitle":4226,"status":61,"phases":4227,"primaryCompletion":1268,"completion":1268,"start":4228,"enrollment":4229,"conditions":4230,"interventions":4231},"NCT01518699","Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers",[38],"2012-01",57,[31],[4218,4232,4233,4234],"Ha44 Placebo","Moxifloxacin Placebo","Moxifloxacin",{"trials":4236,"activeCount":8},[],{"trials":4238,"activeCount":8},[],{"trials":4240,"activeCount":8},[],{"trials":4242,"activeCount":8},[],{"intervention":4232,"totalTrials":46,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4253,"PHASE3":4255,"PHASE4":4257,"NA":4259},{"trials":4246,"activeCount":8},[],{"trials":4248,"activeCount":8},[4249],{"nctId":4225,"briefTitle":4226,"status":61,"phases":4250,"primaryCompletion":1268,"completion":1268,"start":4228,"enrollment":4229,"conditions":4251,"interventions":4252},[38],[31],[4218,4232,4233,4234],{"trials":4254,"activeCount":8},[],{"trials":4256,"activeCount":8},[],{"trials":4258,"activeCount":8},[],{"trials":4260,"activeCount":8},[],{"intervention":4233,"totalTrials":46,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4271,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4264,"activeCount":8},[],{"trials":4266,"activeCount":8},[4267],{"nctId":4225,"briefTitle":4226,"status":61,"phases":4268,"primaryCompletion":1268,"completion":1268,"start":4228,"enrollment":4229,"conditions":4269,"interventions":4270},[38],[31],[4218,4232,4233,4234],{"trials":4272,"activeCount":8},[],{"trials":4274,"activeCount":8},[],{"trials":4276,"activeCount":8},[],{"trials":4278,"activeCount":8},[],{"intervention":4234,"totalTrials":46,"cells":4280},{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4289,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4282,"activeCount":8},[],{"trials":4284,"activeCount":8},[4285],{"nctId":4225,"briefTitle":4226,"status":61,"phases":4286,"primaryCompletion":1268,"completion":1268,"start":4228,"enrollment":4229,"conditions":4287,"interventions":4288},[38],[31],[4218,4232,4233,4234],{"trials":4290,"activeCount":8},[],{"trials":4292,"activeCount":8},[],{"trials":4294,"activeCount":8},[],{"trials":4296,"activeCount":8},[],{"intervention":4298,"totalTrials":46,"cells":4299},"Sumatriptan",{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4311,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4301,"activeCount":8},[],{"trials":4303,"activeCount":8},[4304],{"nctId":4305,"briefTitle":4306,"status":61,"phases":4307,"primaryCompletion":4308,"completion":4308,"start":4308,"enrollment":223,"conditions":4309,"interventions":4310},"NCT01269281","Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions",[38],"2005-07",[13],[4298],{"trials":4312,"activeCount":8},[],{"trials":4314,"activeCount":8},[],{"trials":4316,"activeCount":8},[],{"trials":4318,"activeCount":8},[],{"intervention":4320,"totalTrials":46,"cells":4321},"Doxorubicin Hydrochloride Liposome",{"EARLY_PHASE1":4322,"PHASE1":4324,"PHASE2":4334,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4323,"activeCount":8},[],{"trials":4325,"activeCount":8},[4326],{"nctId":4327,"briefTitle":4328,"status":61,"phases":4329,"primaryCompletion":4330,"completion":763,"start":233,"enrollment":2406,"conditions":4331,"interventions":4333},"NCT02260544","Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection",[38],"2015-04",[4332],"Ovarian Epithelial Cancer Recurrent",[4320],{"trials":4335,"activeCount":8},[],{"trials":4337,"activeCount":8},[],{"trials":4339,"activeCount":8},[],{"trials":4341,"activeCount":8},[],{"intervention":4343,"totalTrials":46,"cells":4344},"DFN-15 Dose 1",{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4362,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4346,"activeCount":8},[],{"trials":4348,"activeCount":8},[4349],{"nctId":4350,"briefTitle":4351,"status":61,"phases":4352,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":4356,"conditions":4357,"interventions":4358},"NCT03051685","Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults",[38],"2015-08-14","2015-11-10","2015-07-20",16,[13],[4343,4359,4360,4361],"DFN-15 Dose 2","DFN-15 Dose 3","Active Comparator",{"trials":4363,"activeCount":8},[],{"trials":4365,"activeCount":8},[],{"trials":4367,"activeCount":8},[],{"trials":4369,"activeCount":8},[],{"intervention":4359,"totalTrials":46,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4373,"activeCount":8},[],{"trials":4375,"activeCount":8},[4376],{"nctId":4350,"briefTitle":4351,"status":61,"phases":4377,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":4356,"conditions":4378,"interventions":4379},[38],[13],[4343,4359,4360,4361],{"trials":4381,"activeCount":8},[],{"trials":4383,"activeCount":8},[],{"trials":4385,"activeCount":8},[],{"trials":4387,"activeCount":8},[],{"intervention":4360,"totalTrials":46,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4391,"activeCount":8},[],{"trials":4393,"activeCount":8},[4394],{"nctId":4350,"briefTitle":4351,"status":61,"phases":4395,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":4356,"conditions":4396,"interventions":4397},[38],[13],[4343,4359,4360,4361],{"trials":4399,"activeCount":8},[],{"trials":4401,"activeCount":8},[],{"trials":4403,"activeCount":8},[],{"trials":4405,"activeCount":8},[],{"intervention":4361,"totalTrials":46,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4422},{"trials":4409,"activeCount":8},[],{"trials":4411,"activeCount":8},[4412],{"nctId":4350,"briefTitle":4351,"status":61,"phases":4413,"primaryCompletion":4353,"completion":4354,"start":4355,"enrollment":4356,"conditions":4414,"interventions":4415},[38],[13],[4343,4359,4360,4361],{"trials":4417,"activeCount":8},[],{"trials":4419,"activeCount":8},[],{"trials":4421,"activeCount":8},[],{"trials":4423,"activeCount":8},[],{"intervention":4425,"totalTrials":46,"cells":4426},"Primidone",{"EARLY_PHASE1":4427,"PHASE1":4429,"PHASE2":4437,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4428,"activeCount":8},[],{"trials":4430,"activeCount":8},[4431],{"nctId":4432,"briefTitle":4433,"status":61,"phases":4434,"primaryCompletion":1469,"completion":1469,"start":1471,"enrollment":266,"conditions":4435,"interventions":4436},"NCT01132040","Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions",[38],[13],[4425],{"trials":4438,"activeCount":8},[],{"trials":4440,"activeCount":8},[],{"trials":4442,"activeCount":8},[],{"trials":4444,"activeCount":8},[],{"intervention":4446,"totalTrials":46,"cells":4447},"Lansoprazole",{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4459,"PHASE3":4461,"PHASE4":4463,"NA":4465},{"trials":4449,"activeCount":8},[],{"trials":4451,"activeCount":8},[4452],{"nctId":4453,"briefTitle":4454,"status":61,"phases":4455,"primaryCompletion":4456,"completion":4456,"start":4456,"enrollment":1802,"conditions":4457,"interventions":4458},"NCT01270308","Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions",[38],"2008-12",[13],[4446],{"trials":4460,"activeCount":8},[],{"trials":4462,"activeCount":8},[],{"trials":4464,"activeCount":8},[],{"trials":4466,"activeCount":8},[],{"intervention":4468,"totalTrials":32,"cells":4469},"Levofloxacin",{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4490},{"trials":4471,"activeCount":8},[],{"trials":4473,"activeCount":8},[],{"trials":4475,"activeCount":8},[],{"trials":4477,"activeCount":8},[],{"trials":4479,"activeCount":8},[4480],{"nctId":4481,"briefTitle":4482,"status":151,"phases":4483,"primaryCompletion":4484,"completion":4484,"start":4485,"enrollment":4486,"conditions":4487,"interventions":4489},"NCT03160807","Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections",[41],"2018-03","2017-04-15",214,[4488],"Urinary Tract Infection",[4468,4468],{"trials":4491,"activeCount":8},[4492],{"nctId":4493,"briefTitle":4494,"status":61,"phases":4495,"primaryCompletion":4101,"completion":4101,"start":221,"enrollment":4123,"conditions":4496,"interventions":4498},"NCT02712502","Levofloxacin in Bacterial Rhinosinussitis",[],[4497],"Rhinosinusitis",[4468,4499],"Amoxicillin-Potassium Clavulanate Combination",{"intervention":4501,"totalTrials":46,"cells":4502},"NISELAT",{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4504,"activeCount":8},[],{"trials":4506,"activeCount":8},[],{"trials":4508,"activeCount":8},[],{"trials":4510,"activeCount":8},[],{"trials":4512,"activeCount":8},[],{"trials":4514,"activeCount":8},[4515],{"nctId":4516,"briefTitle":4517,"status":61,"phases":4518,"primaryCompletion":3226,"completion":3226,"start":1294,"enrollment":4519,"conditions":4520,"interventions":4521},"NCT02865161","Amtolmetin Gaucil in Knee Osteoarthritis",[],220,[183],[4501],{"intervention":4499,"totalTrials":46,"cells":4523},{"EARLY_PHASE1":4524,"PHASE1":4526,"PHASE2":4528,"PHASE3":4530,"PHASE4":4532,"NA":4534},{"trials":4525,"activeCount":8},[],{"trials":4527,"activeCount":8},[],{"trials":4529,"activeCount":8},[],{"trials":4531,"activeCount":8},[],{"trials":4533,"activeCount":8},[],{"trials":4535,"activeCount":8},[4536],{"nctId":4493,"briefTitle":4494,"status":61,"phases":4537,"primaryCompletion":4101,"completion":4101,"start":221,"enrollment":4123,"conditions":4538,"interventions":4539},[],[4497],[4468,4499],{"intervention":4541,"totalTrials":46,"cells":4542},"Levofloxacin 500",{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4544,"activeCount":8},[],{"trials":4546,"activeCount":8},[],{"trials":4548,"activeCount":8},[],{"trials":4550,"activeCount":8},[],{"trials":4552,"activeCount":8},[],{"trials":4554,"activeCount":8},[4555],{"nctId":4556,"briefTitle":4557,"status":61,"phases":4558,"primaryCompletion":235,"completion":210,"start":1244,"enrollment":4559,"conditions":4560,"interventions":4562},"NCT02711943","Non Interventional Study of Levofloxacin in Chronic Prostatitis",[],500,[4561],"Chronic Prostatitis",[4541]]